Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,2.7150840759277344,2.7150840759277344,2.527837038040161,2.544858932495117,41586,0.0,0.0,,,,,,,,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-06-28,2.642738103866577,2.642738103866577,2.5108139514923096,2.5533699989318848,17448,0.0,0.0,,,,,,,100.0,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-06-29,2.544858932495117,2.706573009490967,2.523581027984619,2.523581027984619,19334,0.0,0.0,,,,,,,20.967609305603872,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-06-30,2.5874149799346924,2.6384830474853516,2.4257020950317383,2.6384830474853516,49925,0.0,0.0,,,,,,,81.54713172571951,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-01,2.523581027984619,2.7321059703826904,2.523581027984619,2.6172049045562744,28749,0.0,0.0,,,,,,,70.7342549744543,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-04,2.6342270374298096,2.6342270374298096,2.519325017929077,2.5533699989318848,8253,0.0,0.0,,,,,,,49.52018478355843,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-05,2.4725139141082764,2.625715970993042,2.404423952102661,2.4682579040527344,48759,0.0,0.0,,,,,,,34.614065991505754,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-06,2.4299569129943848,2.59592604637146,2.4299569129943848,2.4682579040527344,15608,0.0,0.0,,,,,,,34.614065991505754,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-07,2.583159923553467,2.583159923553467,2.4682579040527344,2.583159923553467,15347,0.0,0.0,,,,,,,55.5587671511232,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-08,2.5533699989318848,2.583159923553467,2.481024980545044,2.481024980545044,14196,0.0,0.0,2.543156862258911,,,-2.443100645340442,,,42.52050698083249,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-11,2.4852800369262695,2.544858932495117,2.4171910285949707,2.4171910285949707,41299,0.0,0.0,2.5303900718688963,,,-4.473580754698387,,,36.72039415404315,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-12,2.4171910285949707,2.5576260089874268,2.4086790084838867,2.4682579040527344,41098,0.0,0.0,2.5218788623809814,,,-2.1262305310581744,,,43.37494683769606,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-13,2.404423952102661,2.540602922439575,2.404423952102661,2.4682579040527344,4610,0.0,0.0,2.516346549987793,,,-1.911050206311685,,,43.37494683769606,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-14,2.4682579040527344,2.583159923553467,2.4682579040527344,2.4682579040527344,12904,0.0,0.0,2.4993240356445314,,,-1.242981348106215,,,43.37494683769606,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-15,2.583159923553467,2.583159923553467,2.4725139141082764,2.5363481044769287,34273,0.0,0.0,2.4912383556365967,,,1.8107359634323288,,,51.81369628176207,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-18,2.5533699989318848,2.8767969608306885,2.549114942550659,2.8767969608306885,17794,0.0,0.0,2.523581051826477,,,13.996614404303227,,,73.26631315205303,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-19,2.7746620178222656,2.7746620178222656,2.498047113418579,2.6086928844451904,31445,0.0,0.0,2.537624549865723,,,2.800585081951077,,,53.18533770472947,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-20,2.544858932495117,2.6555049419403076,2.544858932495117,2.6555049419403076,20638,0.0,0.0,2.55634925365448,,,3.878800525557201,,,55.4797781167047,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-21,2.6555049419403076,2.6555049419403076,2.5533699989318848,2.6086928844451904,46987,0.0,0.0,2.558902549743652,,,1.9457690839585196,,,52.69829677706486,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-22,2.6555049419403076,2.698060989379883,2.4682579040527344,2.646994113922119,60857,0.0,0.0,2.5754994630813597,,,2.775952853634936,,,54.69946869362539,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-25,2.6767830848693848,2.8087069988250732,2.5150699615478516,2.6384830474853516,21939,0.0,0.0,2.597628664970398,,,1.5727568403399568,,,54.15122723656837,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-26,2.8044519424438477,2.8044519424438477,2.5576260089874268,2.668272018432617,20817,0.0,0.0,2.6176300764083864,,,1.9346485387926118,,,55.82027208119317,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-27,2.706573009490967,2.706573009490967,2.578903913497925,2.578903913497925,2890,0.0,0.0,2.628694677352905,,,-1.8941250303409016,,,49.94601602033557,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-28,2.7533841133117676,2.7533841133117676,2.5533699989318848,2.6938059329986572,17151,0.0,0.0,2.6512494802474977,,,1.6051470473909073,,,56.311838072228866,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-07-29,2.6384830474853516,2.6767830848693848,2.5533699989318848,2.5874149799346924,86295,0.0,0.0,2.656356167793274,,,-2.595329221828469,,,49.9742520420017,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-01,2.5874149799346924,2.6767830848693848,2.502302885055542,2.6172049045562744,90955,0.0,0.0,2.6303969621658325,,,-0.5015234506162122,,,51.616251702182886,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-02,2.540602922439575,2.5916709899902344,2.4852800369262695,2.5916709899902344,18737,0.0,0.0,2.628694772720337,,,-1.4084473828731368,,,50.098377386775965,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-03,2.5874149799346924,2.5916709899902344,2.481024980545044,2.5874149799346924,51612,0.0,0.0,2.6218857765197754,,,-1.314732964104892,,,49.83531636898562,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-04,2.5916709899902344,2.668272018432617,2.4682579040527344,2.5108139514923096,35961,0.0,0.0,2.612097883224487,,,-3.8774937333951804,,,45.23176484793641,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-05,2.476768970489502,2.59592604637146,2.476768970489502,2.59592604637146,28403,0.0,0.0,2.6069910764694213,,,-0.42443682288879997,,,50.68298739352442,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-08,2.59592604637146,2.6342270374298096,2.4171910285949707,2.5916709899902344,28170,0.0,0.0,2.6023098707199095,,,-0.40882451584184126,,,50.41283735760944,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-09,2.4171910285949707,2.5576260089874268,2.4129350185394287,2.527837038040161,17090,0.0,0.0,2.588266372680664,,,-2.3347417127672356,,,46.41578683464785,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-10,2.4427239894866943,2.6299710273742676,2.383146047592163,2.4937920570373535,54752,0.0,0.0,2.579755187034607,,,-3.332220453680601,,,44.394118180038895,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-11,2.4682579040527344,2.5320920944213867,2.395911931991577,2.5320920944213867,40466,0.0,0.0,2.56358380317688,,,-1.2284251724662851,,,47.181284473585016,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-12,2.400167942047119,2.540602922439575,2.400167942047119,2.4682579040527344,84991,0.0,0.0,2.551668095588684,,,-3.2688495686468317,,,43.28691111801267,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-15,2.404423952102661,2.459747076034546,2.400167942047119,2.459747076034546,30523,0.0,0.0,2.535922312736511,,,-3.0038474096536745,,,42.77990778678404,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-16,2.4427239894866943,2.455491065979004,2.3618669509887695,2.4086790084838867,12268,0.0,0.0,2.5176231145858763,,,-4.32726032227861,,,39.76987816257419,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-17,2.4214460849761963,2.4214460849761963,2.3405890464782715,2.4171910285949707,20488,0.0,0.0,2.500600719451904,,,-3.3355861336877366,,,40.52108898245075,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-18,2.3405890464782715,2.4171910285949707,2.3405890464782715,2.3916571140289307,2308,0.0,0.0,2.4886850357055663,,,-3.8987626109596185,,,38.95165361372056,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-19,2.4469799995422363,2.4469799995422363,2.2980329990386963,2.3661229610443115,36613,0.0,0.0,2.4657047271728514,2.547838032245636,,-4.038673610473999,-3.2236470306706755,,37.39199446656878,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-22,2.3405890464782715,2.3618669509887695,2.2469658851623535,2.3618669509887695,58528,0.0,0.0,2.442724323272705,2.5432632327079774,,-3.3101308859775385,-3.953146026816183,,37.125162392581856,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-23,2.3874011039733887,2.4682579040527344,2.2639880180358887,2.2639880180358887,84534,0.0,0.0,2.4163394212722777,2.5360286831855774,,-6.305049774678233,-4.71955473953688,,31.54920894196765,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-24,2.255476951599121,2.459747076034546,2.212920904159546,2.255476951599121,100309,0.0,0.0,2.3925079107284546,2.52932608127594,,-5.727502864875011,-5.409273701810178,,31.111633411265956,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-25,2.212920904159546,2.4214460849761963,2.161853075027466,2.336333990097046,38633,0.0,0.0,2.3729321002960204,2.5217723548412323,,-1.5423159471949892,-5.90220819335545,,39.67216660671571,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-26,2.4257020950317383,2.4257020950317383,2.2256879806518555,2.3703789710998535,15333,0.0,0.0,2.3631442070007322,2.515601706504822,,0.30614991999593316,-6.060478457693297,,42.890164717714306,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-29,2.374634027481079,2.3874011039733887,2.2980329990386963,2.2980329990386963,26150,0.0,0.0,2.3469727993011475,2.509218281507492,,-2.0852308248746616,-6.4659772090003464,,38.224095112577736,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-30,2.2980329990386963,2.3874011039733887,2.04695200920105,2.2725000381469727,24645,0.0,0.0,2.3333549022674562,2.504324334859848,,-2.608041496874195,-6.82696846460823,,36.70632528551096,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-08-31,2.255476951599121,2.2767550945281982,2.1192970275878906,2.187386989593506,61745,0.0,0.0,2.3103744983673096,2.4973025619983673,,-5.32327156747602,-7.485198889215729,,32.126842825224415,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-01,2.1490869522094727,2.6597609519958496,2.1490869522094727,2.353355884552002,37739,0.0,0.0,2.306544375419617,2.491557461023331,,2.029508282227127,-7.425599790410835,,46.21751202789377,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-02,2.2214319705963135,2.3448450565338135,2.1448309421539307,2.3022890090942383,17589,0.0,0.0,2.3001609802246095,2.4870890617370605,,0.0925165189708164,-7.5159383870996,,43.2428018398383,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-05,2.5108139514923096,2.5108139514923096,2.161853075027466,2.2937779426574707,31882,0.0,0.0,2.2933520793914797,2.4840037345886232,,0.018569467366913513,-7.6751758679910935,,42.74895421365405,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-06,2.208664894104004,2.208664894104004,1.957584023475647,2.0384409427642822,128116,0.0,0.0,2.270797371864319,2.4732583105564117,,-10.232371764164611,-8.186000541388859,,31.227044238591944,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-07,2.106529951095581,2.1533420085906982,2.0043959617614746,2.0767409801483154,61027,0.0,0.0,2.252923774719238,2.463470387458801,,-7.820184444228645,-8.546748270708985,,34.09636108275599,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-08,2.127808094024658,2.127808094024658,2.042695999145508,2.042695999145508,15478,0.0,0.0,2.2235599756240845,2.452831339836121,,-8.13398237337015,-9.347212769523502,,32.786879241050784,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-09,2.042695999145508,2.3022890090942383,2.042695999145508,2.136320114135742,91660,0.0,0.0,2.2001540899276733,2.4428306400775908,,-2.901341141702921,-9.934235561340817,,39.65094216169699,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-12,2.136320114135742,2.136320114135742,1.966094970703125,1.9873729944229126,78137,0.0,0.0,2.169088089466095,2.4205950409173966,,-8.37748802944698,-10.39029441934168,,33.74642910567563,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-13,1.9873729944229126,2.161853075027466,1.9192830324172974,2.085252046585083,41794,0.0,0.0,2.150363290309906,2.407509019970894,,-3.027918306559224,-10.680987175038574,,40.06282279154736,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-14,2.0043959617614746,2.085252046585083,1.9958839416503906,2.0384409427642822,37085,0.0,0.0,2.1354686856269836,2.3920824199914934,,-4.543627519137024,-10.72762929152844,,38.18771028871854,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-15,2.042695999145508,2.1533420085906982,1.9448169469833374,2.127808094024658,2683,0.0,0.0,2.1129139065742493,2.38006030023098,,0.7049121785826792,-11.22435400610668,,43.61363310915804,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-16,2.1192970275878906,2.127808094024658,2.1192970275878906,2.127808094024658,810,0.0,0.0,2.0954658150672913,2.3670806497335435,,1.5434410203598694,-11.474675976791376,,43.61363310915803,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-19,2.17036509513855,2.17036509513855,1.9192830324172974,2.0341849327087402,26711,0.0,0.0,2.069506514072418,2.351973196864128,,-1.7067634783217596,-12.00977473588225,,39.41039212022353,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-20,1.9192830324172974,2.012907028198242,1.6852240562438965,1.7660809755325317,288697,0.0,0.0,2.0422705173492433,2.329418420791626,,-13.523651223991159,-12.327021237549879,,30.38083681023309,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-21,1.7660809755325317,1.7660809755325317,1.6273479461669922,1.7575700283050537,55241,0.0,0.0,2.010353422164917,2.3088850736618043,,-12.574077327540001,-12.929688658059854,,30.144720372130124,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-22,0.9362350106239319,0.9447469711303711,0.7923960089683533,0.8341010212898254,802043,0.0,0.0,1.8894939243793487,2.2623924508690836,,-55.855850578413126,-16.482486331957492,,15.797912101229898,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-23,0.8664429783821106,0.8834660053253174,0.8077160120010376,0.8732519745826721,123170,0.0,0.0,1.7631871104240417,2.219538375735283,,-50.47309673375179,-20.560638658030065,,17.588665087136448,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-26,0.9192129969596863,1.004325032234192,0.8264409899711609,0.8647410273551941,117814,0.0,0.0,1.65092391371727,2.175726778805256,,-47.620782510314655,-24.12080736424855,,17.501526803634235,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-27,0.8375049829483032,0.850271999835968,0.8085669875144958,0.850271999835968,39159,0.0,0.0,1.5274259090423583,2.1321918040513994,,-44.33301184677047,-28.363578448239004,,17.344209404426365,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-28,0.8170779943466187,0.8213340044021606,0.7668619751930237,0.800055980682373,118504,0.0,0.0,1.4035874128341674,2.0875078290700912,,-42.999205224641116,-32.76253179565728,,16.780452202925247,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-29,0.8230360150337219,0.8919770121574402,0.7711169719696045,0.850271999835968,18838,0.0,0.0,1.2758338034152985,2.045994280278683,,-33.35558302657742,-37.64235727767927,,19.594979372380863,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-09-30,0.8562300205230713,0.8613370060920715,0.8255890011787415,0.8511229753494263,53552,0.0,0.0,1.1481652915477754,2.0023742035031318,,-25.871041250334564,-42.6598040696353,,19.644576297807447,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-03,0.8511229753494263,0.8511229753494263,0.8179290294647217,0.8485699892044067,24260,0.0,0.0,1.029603797197342,1.9587966784834863,,-17.58286133809167,-47.4369234690316,,19.605504294176384,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-04,0.7923960089683533,0.846867024898529,0.7923960089683533,0.8281430006027222,87368,0.0,0.0,0.935809999704361,1.9163043275475502,,-11.505219984361432,-51.16589853439444,,19.275163910925798,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-05,0.8289939761161804,0.846015989780426,0.7660109996795654,0.8247380256652832,51397,0.0,0.0,0.8425267994403839,1.8745779767632484,,-2.1113599931677185,-55.05512121212808,,19.217038722703677,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-06,0.7915440201759338,0.8213340044021606,0.7915440201759338,0.8085669875144958,15009,0.0,0.0,0.8399733960628509,1.8314898490905762,,-3.7389765789683533,-54.13715252203344,,18.92515200409639,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-07,0.78643798828125,0.8851680159568787,0.783033013343811,0.800055980682373,198593,0.0,0.0,0.832653796672821,1.789784801006317,,-3.9149303252690033,-53.47743504109229,,18.763614970862648,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-10,0.8936790227890015,0.9362350106239319,0.8009070158004761,0.8902750015258789,52186,0.0,0.0,0.8352071940898895,1.7505479991436004,,6.593310956330519,-52.28881501686969,,25.97642714028089,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-11,0.8511229753494263,0.8885729908943176,0.8221849799156189,0.8885729908943176,29652,0.0,0.0,0.8390372931957245,1.7125453487038613,,5.903873177069591,-51.00641896398543,,25.929653670073108,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-12,0.8885729908943176,0.9958140254020691,0.8511229753494263,0.9362350106239319,109468,0.0,0.0,0.8526551961898804,1.6755214482545853,,9.802299312492414,-49.111054527048665,,29.744652577543107,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-13,0.9532579779624939,0.9532579779624939,0.9515560269355774,0.9515560269355774,1555,0.0,0.0,0.8627835988998414,1.6395189210772514,,10.289072271300956,-47.37580714634592,,30.975357742724626,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-14,0.9941120147705078,1.2341289520263672,0.9838979840278625,1.021347999572754,182562,0.0,0.0,0.8798061013221741,1.6058995470404624,,16.08785140701689,-45.214126067624676,,36.43767584924818,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-17,1.021347999572754,1.075819969177246,0.8511229753494263,0.9600669741630554,188456,0.0,0.0,0.890955799818039,1.5708545476198197,,7.756970026922898,-43.28209437544505,,33.900860920940005,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-18,0.9021909832954407,1.0707130432128906,0.9021909832954407,1.0707130432128906,43327,0.0,0.0,0.9152128040790558,1.5410226732492447,,16.9906101008179,-40.61003644097393,,41.78201687468276,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-19,1.0724149942398071,1.075819969177246,0.977088987827301,0.977088987827301,46106,0.0,0.0,0.9304479002952576,1.5090629741549493,,5.012756492571254,-38.3426724907691,,37.68728802497806,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-20,0.9787920117378235,1.0553929805755615,0.9072970151901245,0.9072970151901245,28315,0.0,0.0,0.9403209030628205,1.4733370497822762,,-3.5119806190769856,-36.17747526258317,,34.938491422768806,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-21,0.9089999794960022,1.0162409543991089,0.9072970151901245,0.9464489817619324,9327,0.0,0.0,0.9549602031707763,1.437738800048828,,-0.8912645134932291,-33.579019837376286,,37.6843468106978,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-24,1.040073037147522,1.0417749881744385,0.9702799916267395,0.9702799916267395,7834,0.0,0.0,0.9629607021808624,1.4045449748635292,,0.7600818423120259,-31.43966769206325,,39.36188634311528,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-25,1.0247520208358765,1.0468820333480835,0.8596339821815491,0.9107019901275635,137622,0.0,0.0,0.965173602104187,1.370500023663044,,-5.643711334196179,-29.575075852644567,,36.701826211104446,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-26,0.9107019901275635,0.9107019901275635,0.8511229753494263,0.9089999794960022,38070,0.0,0.0,0.962450098991394,1.3385403484106064,,-5.553547093132955,-28.097042413834224,,36.625677555598585,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-27,0.9049999713897705,1.0,0.8009999990463257,0.8399999737739563,186884,0.0,0.0,0.9512944936752319,1.3007064506411552,,-11.699270903093348,-26.863244723180102,,33.58358025887378,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-28,0.9190000295639038,0.9440000057220459,0.8410000205039978,0.8870000243186951,159143,0.0,0.0,0.937859696149826,1.2653242260217668,,-5.422951006416417,-25.879890951072927,,37.39784304867637,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-10-31,0.9779999852180481,0.9779999852180481,0.7509999871253967,0.8270000219345093,279683,0.0,0.0,0.9245530009269715,1.2286547780036927,,-10.55136686535591,-24.75079107011842,,34.66121041651836,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-01,0.8259999752044678,0.8259999752044678,0.7120000123977661,0.7599999904632568,218822,0.0,0.0,0.8934816956520081,1.196693754196167,,-14.93950081331487,-25.3374814969123,,31.85775569291468,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-02,0.7400000095367432,0.7720000147819519,0.7400000095367432,0.7590000033378601,88172,0.0,0.0,0.871672797203064,1.1637502297759057,,-12.926042229003478,-25.09794843426882,,31.816393376304617,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-03,0.7590000033378601,0.7760000228881836,0.7590000033378601,0.7599999904632568,3240,0.0,0.0,0.8569430947303772,1.1316828295588492,,-11.312665317365315,-24.27709669639245,,31.9115956930073,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-04,0.7509999871253967,0.7979999780654907,0.7480000257492065,0.7649999856948853,89858,0.0,0.0,0.8387981951236725,1.097399826347828,,-8.798088724774427,-23.56494187581455,,32.41969378870965,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-07,0.7749999761581421,0.7749999761581421,0.718999981880188,0.7360000014305115,301152,0.0,0.0,0.8153701961040497,1.066115501523018,,-9.734252619580637,-23.519525329175085,,30.975880843583383,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-08,0.7360000014305115,0.7950000166893005,0.7099999785423279,0.7360000014305115,607817,0.0,0.0,0.7978999972343445,1.0323842003941537,,-7.757863895023033,-22.712881800233436,,30.97588084358337,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-09,0.7360000014305115,0.75,0.7200000286102295,0.75,113146,0.0,0.0,0.7819999992847443,1.0001731768250466,,-4.092071523531081,-21.813540154403263,,32.65509604264119,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-10,0.7509999871253967,0.7509999871253967,0.75,0.75,71968,0.0,0.0,0.7730000019073486,0.96572797447443,,-2.9754206792492868,-19.95675569737618,,32.65509604264119,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-11,0.75,0.7509999871253967,0.699999988079071,0.699999988079071,159840,0.0,0.0,0.7542999982833862,0.9300327718257904,,-7.198728666033349,-18.89533131154239,,29.665774337604176,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-14,0.7200000286102295,0.7889999747276306,0.7200000286102295,0.7419999837875366,621136,0.0,0.0,0.7457999944686889,0.8977281481027604,,-0.5095214144992674,-16.923625927866155,,35.044752183914284,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-15,0.753000020980835,0.7710000276565552,0.7319999933242798,0.7480000257492065,142587,0.0,0.0,0.7445999979972839,0.8722761243581771,,0.4566247328857782,-14.63712267200224,,35.80011743772995,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-16,0.7480000257492065,0.7480000257492065,0.6959999799728394,0.7179999947547913,69467,0.0,0.0,0.7404999971389771,0.8462868735194207,,-3.038487842149581,-12.50012019452834,,33.69050636035942,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-17,0.7379999756813049,0.7379999756813049,0.6499999761581421,0.699999988079071,42839,0.0,0.0,0.7344999969005584,0.8429343476891518,,-4.69707405950585,-12.863914145373107,,32.45475272532458,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-18,0.699999988079071,0.7760000228881836,0.6809999942779541,0.7360000014305115,151207,0.0,0.0,0.731599998474121,0.8395030483603477,,0.6014219471797971,-12.853205250055321,,37.40026761652145,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-21,0.6909999847412109,0.7459999918937683,0.6899999976158142,0.7459999918937683,37535,0.0,0.0,0.7325999975204468,0.8365345224738121,,1.829101067250211,-12.424415509596496,,38.74198560036697,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-22,0.699999988079071,0.7419999837875366,0.699999988079071,0.7419999837875366,55020,0.0,0.0,0.7331999957561492,0.8338277220726014,,1.2002165960614806,-12.068167518624485,,38.387559872319024,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-23,0.7419999837875366,0.7419999837875366,0.699999988079071,0.7200000286102295,79323,0.0,0.0,0.7301999986171722,0.8318263232707978,,-1.3968734629223611,-12.217252785896928,,36.414400618764056,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-24,0.7300000190734863,0.8069999814033508,0.6800000071525574,0.7170000076293945,64673,0.0,0.0,0.7268999993801117,0.8284945234656333,,-1.361946864652601,-12.2625462459965,,36.14158701026281,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-25,0.7250000238418579,0.7250000238418579,0.6019999980926514,0.6499999761581421,245463,0.0,0.0,0.7218999981880188,0.8234664484858513,,-9.9598313077084,-12.334011966679128,,30.62355874639728,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-28,0.6449999809265137,0.6449999809265137,0.6000000238418579,0.6000000238418579,131876,0.0,0.0,0.707700002193451,0.8172521993517876,,-15.21830973827708,-13.40494369366386,,27.276628527118618,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-29,0.6489999890327454,0.6489999890327454,0.5649999976158142,0.5910000205039978,93005,0.0,0.0,0.69200000166893,0.8113236248493194,,-14.595372965512382,-14.707278270437444,,26.71073515898499,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-11-30,0.5830000042915344,0.6340000033378601,0.5699999928474426,0.5899999737739563,174032,0.0,0.0,0.6791999995708465,0.8054551735520363,,-13.13310156849991,-15.675009376922588,,26.644587386899502,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-01,0.5899999737739563,0.6990000009536743,0.5889999866485596,0.6190000176429749,22801,0.0,0.0,0.6711000025272369,0.8007159993052483,,-7.763371284169759,-16.18751178825881,,31.910487861276607,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-02,0.6200000047683716,0.734000027179718,0.6200000047683716,0.6380000114440918,85442,0.0,0.0,0.661300003528595,0.7966646000742912,,-3.5233618569753524,-16.991416027908492,,35.19296796750112,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-05,0.6380000114440918,0.6710000038146973,0.6039999723434448,0.6039999723434448,60964,0.0,0.0,0.6471000015735626,0.7895077243447304,,-6.660489742746225,-18.037533817590226,,32.20134705516077,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-06,0.6039999723434448,0.6980000138282776,0.5709999799728394,0.6499999761581421,45937,0.0,0.0,0.6379000008106231,0.783543398976326,,1.8968451688576071,-18.58778956672741,,39.673135305555206,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-07,0.6499999761581421,0.6589999794960022,0.6119999885559082,0.6399999856948853,12885,0.0,0.0,0.6298999965190888,0.7761375233530998,,1.603427406193102,-18.841702975811543,,38.67528943505149,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-08,0.6930000185966492,0.6930000185966492,0.6140000224113464,0.6800000071525574,15333,0.0,0.0,0.626199996471405,0.7693486228585243,,8.591506065843472,-18.60647073822643,,44.670058702812234,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-09,0.6159999966621399,0.6880000233650208,0.6159999966621399,0.6740000247955322,18289,0.0,0.0,0.628600001335144,0.7606649234890938,1.6381341675917307,7.222402698688944,-17.36177363722533,-53.565163431798155,43.97563660467732,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-12,0.6740000247955322,0.6740000247955322,0.6000000238418579,0.6000000238418579,59603,0.0,0.0,0.628600001335144,0.7516632497310638,1.6219270100196204,-4.549789601104023,-16.372125208988244,-53.656160536967015,36.44960164836948,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-13,0.5979999899864197,0.5979999899864197,0.5509999990463257,0.5699999928474426,248890,0.0,0.0,0.6264999985694886,0.7391454234719277,1.6053989266355833,-9.018356879657553,-15.23995432093984,-53.958769299731216,33.91548398288862,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-14,0.5580000281333923,0.5720000267028809,0.515999972820282,0.5709999799728394,490971,0.0,0.0,0.6245999991893768,0.7289931982755661,1.5891274179021517,-8.581495242731515,-14.320188354724223,-54.12619591964949,34.080000147554614,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-15,0.5479999780654907,0.5910000205039978,0.5479999780654907,0.5519999861717224,146882,0.0,0.0,0.6178999960422515,0.720110772550106,1.5717400590578714,-10.665157839881736,-14.193757461216505,-54.18385066919061,32.42813507657931,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-16,0.5830000042915344,0.5889999866485596,0.5009999871253967,0.5009999871253967,823730,0.0,0.0,0.6041999936103821,0.7089745476841927,1.5541050180792808,-17.080438195359175,-14.778323765789342,-54.38052516165126,28.44292974459094,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-19,0.5049999952316284,0.5260000228881836,0.5,0.5260000228881836,272371,0.0,0.0,0.5963999986648559,0.6978675484657287,1.5372102682789166,-11.804154247866332,-14.539657277939142,-54.60168573769211,32.80243693419517,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-20,0.5090000033378601,0.5600000023841858,0.5049999952316284,0.5120000243186951,588670,0.0,0.0,0.5826000034809112,0.687899999320507,1.5209081192811331,-12.118087665704822,-15.307456889607343,-54.77044335553634,31.639938123049802,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-21,0.5149999856948853,0.5249999761581421,0.49000000953674316,0.5180000066757202,222919,0.0,0.0,0.5704000055789947,0.678125,1.5046559701363245,-9.186535482250733,-15.885713463005382,-54.93155821270156,32.74008180357282,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-22,0.5180000066757202,0.5960000157356262,0.5,0.5950000286102295,228152,0.0,0.0,0.561900007724762,0.6720000013709069,1.4880879710117976,5.890731523477931,-16.383927592490547,-54.84137937665117,44.978031047781364,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-23,0.5789999961853027,0.5789999961853027,0.5360000133514404,0.5559999942779541,14338,0.0,0.0,0.5501000046730041,0.6637250006198883,1.4720460961262385,1.072530368084091,-17.11928823545349,-54.91139833416133,40.91718194366422,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-27,0.5350000262260437,0.5590000152587891,0.5099999904632568,0.5230000019073486,29048,0.0,0.0,0.5424000024795532,0.6561250001192093,1.4562611709038416,-3.576696254336007,-17.332824937168027,-54.94455162105438,37.806759346247404,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-28,0.5099999904632568,0.5600000023841858,0.5,0.5350000262260437,221967,0.0,0.0,0.5389000058174134,0.650500001013279,1.4401506885886193,-0.7236926237278682,-17.156033054885032,-54.83111550980932,39.604677662259434,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-29,0.5350000262260437,0.6299999952316284,0.5130000114440918,0.550000011920929,58372,0.0,0.0,0.5368000090122222,0.6452750012278556,1.4241652061541876,2.459016894019121,-16.810660882448992,-54.691000844603224,41.86694195777654,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2022-12-30,0.5049999952316284,0.5550000071525574,0.5049999952316284,0.5529999732971191,368988,0.0,0.0,0.536900007724762,0.6401000007987022,1.4082047233978907,2.9986897635901486,-16.12247976022022,-54.54496138500446,42.3321883466349,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-02,0.5109999775886536,0.6489999890327454,0.5109999775886536,0.6489999890327454,207565,0.0,0.0,0.5517000079154968,0.6372000008821488,1.392476822435856,17.63639291666494,-13.418077973679315,-54.23981278428056,54.79883823921206,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-03,0.6489999890327454,0.6489999890327454,0.5809999704360962,0.6169999837875366,102276,0.0,0.0,0.5608000040054322,0.6342250004410743,1.3736451809604964,10.021394326088497,-11.577121113891513,-53.82905212846857,50.852519199055116,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-04,0.5649999976158142,0.6480000019073486,0.5649999976158142,0.6449999809265137,143108,0.0,0.0,0.574099999666214,0.6319499999284744,1.357281073431174,12.349761592322157,-9.154205280292443,-53.440004999780925,53.97572375894418,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-05,0.6449999809265137,0.6449999809265137,0.5860000252723694,0.6029999852180481,64977,0.0,0.0,0.5825999975204468,0.6282749995589256,1.3401768654584885,3.5015427024414576,-7.269906023722819,-53.11999365516683,48.950743044258815,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-09,0.6110000014305115,0.6880000233650208,0.6039999723434448,0.6769999861717224,50738,0.0,0.0,0.590799993276596,0.6264499992132186,1.3240794246395429,14.59038488085594,-5.6907983049559805,-52.687883554737766,56.6145895504925,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-10,0.675000011920929,0.6769999861717224,0.6209999918937683,0.6769999861717224,73683,0.0,0.0,0.6028999924659729,0.625874999165535,1.3076628069082896,12.29059456489073,-3.6708618702127667,-52.13789091047922,56.6145895504925,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-11,0.6769999861717224,0.6769999861717224,0.6209999918937683,0.6299999952316284,187141,0.0,0.0,0.6135999917984009,0.6230749994516372,1.2909254481395085,2.672751573082779,-1.5206849354532375,-51.734238383043916,50.977308465614065,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-12,0.6769999861717224,0.6769999861717224,0.6000000238418579,0.6320000290870667,120029,0.0,0.0,0.6232999920845032,0.6201749995350838,1.2739565148949623,1.395802520944682,0.5038888300499048,-51.3189820622553,51.19999065802626,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-13,0.6539999842643738,0.6740000247955322,0.6000000238418579,0.6510000228881836,252778,0.0,0.0,0.6333999931812286,0.6185000002384186,1.2578906491398811,2.778659598425229,2.4090530213527006,-50.83038413066067,53.36710348920253,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-16,0.652999997138977,0.6759999990463257,0.6290000081062317,0.6499999761581421,235536,0.0,0.0,0.6430999934673309,0.6172499999403953,1.2408589328328767,1.0729253243510837,4.187929287878789,-50.25623109862975,53.23310652855422,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-17,0.6769999861717224,0.6899999976158142,0.6000000238418579,0.6690000295639038,405674,0.0,0.0,0.6450999975204468,0.6155750006437302,1.224872141579787,3.7048569423842705,4.796328123436008,-49.74373408070264,55.518294638401464,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-18,0.6690000295639038,0.7289999723434448,0.6489999890327454,0.6759999990463257,341619,0.0,0.0,0.6509999990463257,0.6138250008225441,1.2086954340338707,3.8402457813553705,6.056286103362675,-49.21590803284666,56.3642584825245,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-19,0.7279999852180481,0.7279999852180481,0.6330000162124634,0.6589999794960022,135551,0.0,0.0,0.6523999989032745,0.6117500007152558,1.192589842279752,1.0116463218612337,6.644870966978489,-48.70407418984587,53.69352678180717,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-20,0.699999988079071,0.7269999980926514,0.6650000214576721,0.6700000166893005,24791,0.0,0.0,0.6591000020503998,0.6105000004172325,1.176611384252707,1.6537725087227784,7.960688222760469,-48.11370954013206,55.17362158142249,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-23,0.6700000166893005,0.7099999785423279,0.6589999794960022,0.6800000071525574,162922,0.0,0.0,0.6594000041484833,0.6095750004053115,1.1613546013832092,3.124052604560699,8.173728205724105,-47.511724698099194,56.53378097970693,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-24,0.6800000071525574,0.7200000286102295,0.6549999713897705,0.7129999995231628,177473,0.0,0.0,0.6630000054836274,0.6111500009894371,1.1456635509928068,7.541477168324128,8.484006284913098,-46.65536837059817,60.7646767430314,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-25,0.734000027179718,0.7480000257492065,0.6639999747276306,0.7129999995231628,230698,0.0,0.0,0.6713000059127807,0.6139750003814697,1.1300079594055812,6.2118267902711795,9.336700272111138,-45.66631188116238,60.764676743031394,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-26,0.7129999995231628,0.7289999723434448,0.6809999942779541,0.6809999942779541,87309,0.0,0.0,0.6762000024318695,0.6162249997258187,1.1146176507075627,0.7098479486575006,9.73264679828568,-44.714225606006046,54.769216011792516,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-27,0.7099999785423279,0.843999981880188,0.7099999785423279,0.734000027179718,127060,0.0,0.0,0.684500002861023,0.6198250010609627,1.0999527171254158,7.231559402746307,10.434397078103528,-43.649850451681665,61.53804443611582,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-30,0.7799999713897705,0.7799999713897705,0.699999988079071,0.7149999737739563,446426,0.0,0.0,0.6910000026226044,0.6222249999642372,1.0848102827866872,3.473223018851373,11.053076083783216,-42.64204443510155,58.17685495523984,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-01-31,0.7120000123977661,0.746999979019165,0.6850000023841858,0.6850000023841858,192513,0.0,0.0,0.6925999999046326,0.6233999997377395,1.0699498002727827,-1.097314109369521,11.100417099134601,-41.73558426957935,53.23284137784356,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-01,0.7770000100135803,0.7770000100135803,0.6909999847412109,0.6909999847412109,69713,0.0,0.0,0.6940999984741211,0.6255750000476837,1.0552102411786715,-0.44662350377828386,10.95392213902635,-40.71560570252659,54.073475116474626,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-02,0.7009999752044678,0.753000020980835,0.6800000071525574,0.6930000185966492,90289,0.0,0.0,0.6975000023841857,0.6266500011086464,1.0409129162629445,-0.6451589637497905,11.306151942901788,-39.79803773033894,54.36792279014025,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-03,0.6930000185966492,0.7200000286102295,0.6800000071525574,0.7020000219345093,202863,0.0,0.0,0.7007000029087067,0.628200002014637,1.0266196578741074,0.1855314714436994,11.54091064335598,-38.808886309902306,55.74296756160699,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-06,0.7020000219345093,0.777999997138977,0.7020000219345093,0.7020000219345093,191534,0.0,0.0,0.7029000043869018,0.6287500023841858,1.0125391821066538,-0.1280384758536935,11.79324083046414,-37.903637360874235,55.74296756160699,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-07,0.746999979019165,0.746999979019165,0.6850000023841858,0.7269999980926514,50393,0.0,0.0,0.7043000042438508,0.6300750017166138,0.9988798240820567,3.2230574630155995,11.780343978893617,-36.921841193895816,59.65910906993367,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-08,0.7170000076293945,0.7170000076293945,0.6899999976158142,0.7059999704360962,30410,0.0,0.0,0.703600001335144,0.6327250003814697,0.9850809325774511,0.3410985071628818,11.201549000109646,-35.7692368762074,55.23754982554038,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-09,0.7269999980926514,0.7269999980926514,0.699999988079071,0.7200000286102295,72525,0.0,0.0,0.7075000047683716,0.6364750012755394,0.9722143659989039,1.766787810263022,11.159119109233401,-34.53347085428102,57.499027029934055,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-10,0.7919999957084656,0.7919999957084656,0.6800000071525574,0.7649999856948853,86676,0.0,0.0,0.7106000006198883,0.6413250014185905,0.9597937246163686,7.655500285328095,10.801855385033122,-33.1809549312349,63.8253287332108,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-13,0.796999990940094,0.8610000014305115,0.7049999833106995,0.7110000252723694,537723,0.0,0.0,0.7102000057697296,0.6453000023961067,0.9462492749094963,0.11264707070407166,10.057338157855003,-31.80443890349863,53.528527103443786,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-14,0.75,0.7990000247955322,0.6899999976158142,0.7080000042915344,146577,0.0,0.0,0.7125000059604645,0.6504750028252602,0.9323961168527604,-0.6315791763207019,9.535340000123933,-30.236195639585645,53.0168001042458,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-15,0.7400000095367432,0.7400000095367432,0.6800000071525574,0.703000009059906,187793,0.0,0.0,0.7137000083923339,0.6549000024795533,0.9191041752696038,-1.4992292569157362,8.978470864277707,-28.745835336081534,52.12244943535302,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-16,0.6809999942779541,0.718999981880188,0.6539999842643738,0.6779999732971191,176588,0.0,0.0,0.712200003862381,0.6590500012040138,0.9058166747291883,-4.802026169585698,8.064638883433407,-27.242452077728665,47.78218625755891,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-17,0.6809999942779541,0.6809999942779541,0.6499999761581421,0.6629999876022339,101963,0.0,0.0,0.7083000004291534,0.6626750007271767,0.8931134497125943,-6.3955968938970225,6.884973727982922,-25.80169955559097,45.34251264576649,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-20,0.6629999876022339,0.7319999933242798,0.6119999885559082,0.7310000061988831,105926,0.0,0.0,0.7111999988555908,0.666075000166893,0.879593817392985,2.7840280336266745,6.774762403241555,-24.274706461550313,56.248430435509505,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-21,0.7310000061988831,0.7310000061988831,0.6100000143051147,0.6200000047683716,375455,0.0,0.0,0.7004999995231629,0.6676750004291534,0.8655747423569361,-11.49179083648657,4.91631393610828,-22.86339148354851,41.64203291524476,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-22,0.6200000047683716,0.6370000243186951,0.5550000071525574,0.5899999737739563,263447,0.0,0.0,0.6888999998569488,0.6693499997258187,0.8513765926162402,-14.356223850127636,2.9207440261654307,-21.380267494912257,38.715828461228696,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-23,0.640999972820282,0.640999972820282,0.609000027179718,0.609000027179718,48040,0.0,0.0,0.6777999997138977,0.6711999997496605,0.8394645849863688,-10.150482821366252,0.9833134634533426,-20.04427443945602,41.51872691392927,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-24,0.6600000262260437,0.6700000166893005,0.5630000233650208,0.6119999885559082,47881,0.0,0.0,0.6625,0.672749999165535,0.8272584100564321,-7.622643236844041,-1.5235970536230283,-18.67716411373287,41.970018257533866,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-27,0.6800000071525574,0.6800000071525574,0.5899999737739563,0.6349999904632568,19335,0.0,0.0,0.6548999965190887,0.6747999995946884,0.81552760998408,-3.038632793037712,-2.9490223899751666,-17.256020356213174,45.44589608878021,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-02-28,0.675000011920929,0.675000011920929,0.6000000238418579,0.6069999933242798,61074,0.0,0.0,0.6447999954223633,0.6737499997019768,0.8027832756439844,-5.862283245415256,-4.296846648225466,-16.073239173860276,42.136948068383525,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-01,0.6019999980926514,0.6570000052452087,0.6019999980926514,0.6129999756813049,106772,0.0,0.0,0.6357999920845032,0.673649999499321,0.7913301671544711,-3.586035968394283,-5.618645801669886,-14.871184309618062,43.093121576720904,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-02,0.5799999833106995,0.6480000019073486,0.5799999833106995,0.6480000019073486,48675,0.0,0.0,0.6327999949455261,0.6737250000238418,0.7793530667821567,2.4020238753527536,-6.074437652880255,-13.553300969795218,48.44503352034004,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-03,0.6480000019073486,0.6790000200271606,0.6039999723434448,0.6470000147819519,55362,0.0,0.0,0.6311999976634979,0.6748250007629395,0.7677577257156372,2.503171289122413,-6.46463943246328,-12.104433708703333,48.30525215714833,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-06,0.6019999980926514,0.6470000147819519,0.5720000267028809,0.5899999737739563,22849,0.0,0.0,0.6170999944210053,0.6726500004529953,0.7549426580468813,-4.391512055104715,-8.258381921442046,-10.900517637562844,41.03684257961558,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-07,0.5899999737739563,0.6759999990463257,0.5799999833106995,0.5799999833106995,85686,0.0,0.0,0.613099992275238,0.6702250003814697,0.742044257124265,-5.398794549271343,-8.523258319775898,-9.678567828437252,39.90247457356525,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-08,0.5799999833106995,0.6299999952316284,0.5799999833106995,0.5899999737739563,25120,0.0,0.0,0.613099992275238,0.6692249998450279,0.7300093824664752,-3.7677407914419745,-8.386567683930924,-8.326520738141157,41.6398012040365,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-09,0.5899999737739563,0.6600000262260437,0.5899999737739563,0.6600000262260437,12419,0.0,0.0,0.6181999921798706,0.6699249997735024,0.7207920412222545,6.7615714291389,-7.721014682407682,-7.057103649826145,52.08229763473929,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-10,0.6399999856948853,0.6399999856948853,0.5770000219345093,0.5799999833106995,11009,0.0,0.0,0.6149999916553497,0.6681499987840652,0.7109789575139681,-5.691058344642137,-7.954801650144539,-6.023941816739557,42.68258060112316,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-13,0.5799999833106995,0.6389999985694885,0.5,0.5189999938011169,230386,0.0,0.0,0.6033999919891357,0.6648749992251396,0.7083531156182289,-13.987404592066754,-9.24609998987001,-6.137915600913667,37.17346469820159,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-14,0.5,0.5950000286102295,0.5,0.5450000166893005,295979,0.0,0.0,0.5971999943256379,0.6617749989032745,0.7056176826357842,-8.740786693288884,-9.757848919142226,-6.213376565158977,40.68750002472564,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-15,0.5450000166893005,0.5509999990463257,0.5239999890327454,0.5239999890327454,546459,0.0,0.0,0.5882999956607818,0.6579749986529351,0.702778173983097,-10.929798929509484,-10.589308580842447,-6.375151788825982,38.7998400477367,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-16,0.5,0.5669999718666077,0.4950000047683716,0.4964999854564667,454952,0.0,0.0,0.5731499940156937,0.6539124988019467,0.6998300738632679,-13.373464077385682,-12.350659290688052,-6.561246333391003,36.41715652542572,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-17,0.5009999871253967,0.5049999952316284,0.4970000088214874,0.5009999871253967,58431,0.0,0.0,0.5585499912500381,0.6496874980628491,0.6973379405836264,-10.303465227140036,-14.027899118353446,-6.833192308580974,37.09787316092315,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-20,0.5,0.5009999871253967,0.4505000114440918,0.49000000953674316,1099846,0.0,0.0,0.5485499948263168,0.6449374981224537,0.6943356739977996,-10.673591439575512,-14.945247187012821,-7.114451658651554,36.08099542765847,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-21,0.49050000309944153,0.5630000233650208,0.49000000953674316,0.4909999966621399,460141,0.0,0.0,0.5396499961614609,0.6393874980509281,0.6913346491754055,-9.015102352519087,-15.598913365291189,-7.514038416335388,36.25206514484437,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-22,0.5,0.578000009059906,0.460999995470047,0.4894999861717224,387249,0.0,0.0,0.5295999974012375,0.6337999977171421,0.6883423991501332,-7.571754423392567,-16.440517622470534,-7.923731198358872,36.09600684692666,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-23,0.47600001096725464,0.5600000023841858,0.4555000066757202,0.4814999997615814,581941,0.0,0.0,0.5117499947547912,0.6288124978542328,0.685453707476457,-5.91108848134025,-18.616440274152794,-8.263316545584463,35.225072053889775,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-24,0.4790000021457672,0.5149999856948853,0.4675000011920929,0.47999998927116394,191920,0.0,0.0,0.5017499953508378,0.6224624969065189,0.6825808905065059,-4.334829353504148,-19.392734848379096,-8.807511964681062,35.054284069768116,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-27,0.5009999871253967,0.5199999809265137,0.46700000762939453,0.49000000953674316,162351,0.0,0.0,0.49884999692440035,0.6168374978005886,0.6799261656900247,-1.774077867539485,-19.127809398243052,-9.278752763604919,37.2389590139543,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-28,0.49900001287460327,0.49900001287460327,0.4659999907016754,0.4805000126361847,89850,0.0,0.0,0.4923999965190887,0.6117249980568886,0.6772631992896397,-2.4167311062202064,-19.50631442508142,-9.676917526523232,36.0000299307339,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-29,0.4984999895095825,0.5600000023841858,0.4805000126361847,0.5600000023841858,18387,0.0,0.0,0.49599999785423277,0.608449998497963,0.6745109076301257,12.903226775569806,-18.481387282657163,-9.79389782802264,50.76287061579356,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-30,0.5789999961853027,0.5789999961853027,0.5600000023841858,0.5699999928474426,385069,0.0,0.0,0.5033499985933304,0.6053749978542328,0.6718561326464018,13.24128229668686,-16.853190109028716,-9.895144445627626,52.25476271745755,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-03-31,0.5260000228881836,0.5770000219345093,0.5230000019073486,0.5699999928474426,1216,0.0,0.0,0.5102499991655349,0.6020749971270561,0.668804174164931,11.709944885766408,-15.251421899212888,-9.977386448162186,52.25476271745755,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-03,0.5699999928474426,0.6899999976158142,0.5699999928474426,0.5960000157356262,52240,0.0,0.0,0.5208499997854232,0.5994249969720841,0.6658412074049314,14.428341361459701,-13.108395142607002,-9.974782229489781,56.25188594025551,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-04,0.6880000233650208,0.75,0.6460000276565552,0.7200000286102295,481308,0.0,0.0,0.5437500029802322,0.5992499977350235,0.663329974313577,32.41379763935463,-9.261576130924288,-9.660346895203146,69.40652579530001,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-05,0.699999988079071,0.7179999947547913,0.6499999761581421,0.6980000138282776,298976,0.0,0.0,0.5646000057458878,0.599049998819828,0.6611460829774539,23.62734798526194,-5.750770910910482,-9.392188164827028,65.63562442123455,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-06,0.6899999976158142,0.8199999928474426,0.6899999976158142,0.800000011920929,190662,0.0,0.0,0.5964500069618225,0.6010499984025955,0.6588901410500209,34.12691802887937,-0.7653259218032451,-8.77841980686645,72.96853415827806,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-11,0.7879999876022339,0.7879999876022339,0.6859999895095825,0.6859999895095825,239738,0.0,0.0,0.6170500069856644,0.599074998497963,0.6564643993973732,11.174132038462165,3.0004604653456446,-8.742195456767048,58.05728406662818,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-12,0.7480000257492065,0.7480000257492065,0.6880000233650208,0.7200000286102295,99792,0.0,0.0,0.640050008893013,0.5992999985814095,0.654903591175874,12.49121453111025,6.7996012694914105,-8.490347792203853,60.64064768265969,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-13,0.7200000286102295,0.7200000286102295,0.6600000262260437,0.699999988079071,53075,0.0,0.0,0.6620000064373016,0.5990999981760978,0.6528498495618502,5.74017843991795,10.499083367166884,-8.2331107867798,58.36342297442136,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-14,0.699999988079071,0.699999988079071,0.6200000047683716,0.6840000152587891,362738,0.0,0.0,0.6744000077247619,0.59862499833107,0.6504641830921173,1.423488645324142,12.658176588840774,-7.969567903742053,56.534364364119085,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-17,0.699999988079071,0.699999988079071,0.6200000047683716,0.671999990940094,194572,0.0,0.0,0.684600007534027,0.5984749987721443,0.6484749997655551,-1.8404932011787623,14.39074463237067,-7.710397626969039,55.13866876727112,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-18,0.7480000257492065,0.7480000257492065,0.6200000047683716,0.6880000233650208,98284,0.0,0.0,0.6964000105857849,0.599099999666214,0.6466333334644635,-1.2062014780411099,16.241030040691246,-7.350894446406045,56.67450581627309,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-19,0.7459999918937683,0.7459999918937683,0.6620000004768372,0.6959999799728394,29778,0.0,0.0,0.7064000070095062,0.5982249990105629,0.6454333335161209,-1.4722574934129233,18.0826625730887,-7.314207688713808,57.45872052310888,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-20,0.6959999799728394,0.6959999799728394,0.6439999938011169,0.6819999814033508,12117,0.0,0.0,0.7026000022888184,0.5997749984264373,0.6437249998251597,-2.9319699428351926,17.143929662315287,-6.827449828833669,55.56330441702231,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-21,0.7400000095367432,0.7400000095367432,0.6499999761581421,0.6779999732971191,40827,0.0,0.0,0.7005999982357025,0.6019749984145164,0.6424833327531815,-3.2258100193400314,16.383570759740014,-6.304962677409547,55.00500345589854,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-24,0.6520000100135803,0.6520000100135803,0.5879999995231628,0.6159999966621399,322997,0.0,0.0,0.6821999967098236,0.602149997651577,0.6412833328048388,-9.703899203599981,13.294029622261341,-6.1023471453874985,47.10444892887794,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-25,0.5899999737739563,0.6000000238418579,0.5680000185966492,0.5820000171661377,163260,0.0,0.0,0.6717999994754791,0.6013999983668328,0.6398083329200744,-13.367070910904207,11.706019504460455,-6.003100081230057,43.421216093050944,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-26,0.6159999966621399,0.6159999966621399,0.550000011920929,0.5619999766349792,446054,0.0,0.0,0.6559999942779541,0.5995749980211258,0.6381583328048388,-14.32927110714974,9.410832079899398,-6.046044186891867,41.371897005370684,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-27,0.5699999928474426,0.6119999885559082,0.5440000295639038,0.5479999780654907,49885,0.0,0.0,0.6407999932765961,0.598099997639656,0.6363499994079272,-14.481900153680089,7.139273667522398,-6.010843372964527,39.950511932239294,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-04-28,0.5519999861717224,0.6679999828338623,0.49399998784065247,0.6019999980926514,371896,0.0,0.0,0.6325999915599823,0.5978249981999397,0.6352333327134451,-4.837178924373956,5.816918573955684,-5.88891240226846,47.44997023532781,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-02,0.6499999761581421,0.7400000095367432,0.6019999980926514,0.6779999732971191,474344,0.0,0.0,0.6331999897956848,0.598574997484684,0.6347499991456668,7.075171229217799,5.784570430856789,-5.699094400893582,55.81390149675231,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-03,0.699999988079071,0.7099999785423279,0.6800000071525574,0.6880000233650208,326292,0.0,0.0,0.6331999897956848,0.5995999976992608,0.6342333326737086,8.654459010180702,5.603734527243391,-5.4606614301468035,56.78846597976893,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-04,0.6620000004768372,0.6800000071525574,0.6399999856948853,0.6399999856948853,169858,0.0,0.0,0.6275999903678894,0.6008499979972839,0.6333166658878326,1.9757800378115344,4.452025041152853,-5.126450895624932,50.976548518850066,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-05,0.656000018119812,0.7400000095367432,0.6420000195503235,0.6899999976158142,103710,0.0,0.0,0.6283999919891358,0.6035999983549118,0.6332333326339722,9.80267447675961,4.108680202421359,-4.679686420769845,56.02521037722616,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-08,0.6899999976158142,0.699999988079071,0.6359999775886536,0.6359999775886536,85312,0.0,0.0,0.6241999924182892,0.6047499984502792,0.6323499992489815,1.8904173844425474,3.216204054212837,-4.364671595078955,50.03237909908252,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-09,0.6359999775886536,0.699999988079071,0.6060000061988831,0.6539999842643738,202504,0.0,0.0,0.6279999911785126,0.6045999974012375,0.6315666655699412,4.140126345713684,3.8703264766549257,-4.269805491454867,51.880101344272276,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-10,0.7400000095367432,0.7419999837875366,0.656000018119812,0.6600000262260437,56857,0.0,0.0,0.6357999920845032,0.606599998474121,0.6310833324988683,3.806233790944133,4.813714751703533,-3.879572278957492,52.510495185308365,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-11,0.734000027179718,0.734000027179718,0.6140000224113464,0.6499999761581421,55412,0.0,0.0,0.6445999920368195,0.6098749980330467,0.6306666657328606,0.8377263710878453,5.693788746180281,-3.2967760672197755,51.304148021552194,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-12,0.6119999885559082,0.699999988079071,0.6100000143051147,0.699999988079071,140856,0.0,0.0,0.6597999930381775,0.613749997317791,0.6303666656215986,6.092754693097957,7.503054325317161,-2.636032203165764,56.664821998552036,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-15,0.699999988079071,0.699999988079071,0.6359999775886536,0.699999988079071,32189,0.0,0.0,0.6695999920368194,0.6181499972939491,0.6299833322564761,4.540023357792995,8.323221704780535,-1.8783568320993902,56.664821998552036,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-16,0.6919999718666077,0.699999988079071,0.6660000085830688,0.6840000152587891,195697,0.0,0.0,0.6701999962329864,0.6228374980390072,0.6294999991854032,2.059089690147541,7.604310649743982,-1.0583798498836414,54.440645751411985,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-17,0.7440000176429749,0.7459999918937683,0.671999990940094,0.7360000014305115,19807,0.0,0.0,0.6749999940395355,0.628712498396635,0.6296333322922388,9.037038211796364,7.3622674530798236,-0.14624922925402337,59.94360389159888,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-19,0.734000027179718,0.734000027179718,0.6420000195503235,0.7200000286102295,25845,0.0,0.0,0.68299999833107,0.6344624988734722,0.6296583324670791,5.417281166847757,7.650176258451704,0.7629798826880781,57.63675641014734,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-22,0.7200000286102295,0.7200000286102295,0.6499999761581421,0.7080000042915344,44570,0.0,0.0,0.684799998998642,0.639887499064207,0.6301416660348574,3.3878512451543483,7.018811900547591,1.5466098426207715,55.899237730138736,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-23,0.7080000042915344,0.7080000042915344,0.6340000033378601,0.699999988079071,134589,0.0,0.0,0.6912000000476837,0.6451499991118907,0.6309749990701675,1.2731464164902042,7.137875067687367,2.2465232477692667,54.71502433007042,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-24,0.6899999976158142,0.6899999976158142,0.6000000238418579,0.6840000152587891,392195,0.0,0.0,0.6942000031471253,0.650212499499321,0.6317499990264575,-1.4693154482994824,6.765096592525621,2.9224377524835377,52.327398384581294,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-25,0.699999988079071,0.699999988079071,0.6299999952316284,0.671999990940094,784259,0.0,0.0,0.6953999996185303,0.6550124995410442,0.632433332502842,-3.364971051376564,6.165912880408366,3.570205091633247,50.545869257597786,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-26,0.6499999761581421,0.699999988079071,0.6200000047683716,0.6899999976158142,298333,0.0,0.0,0.6994000017642975,0.660012499243021,0.6330249990026157,-1.3440097404591032,5.967690394719904,4.263259789570141,53.12391343504234,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-29,0.6899999976158142,0.699999988079071,0.6620000004768372,0.6899999976158142,236823,0.0,0.0,0.6984000027179718,0.6652499988675118,0.6334583322207133,-1.2027498667621916,4.98308965154346,5.018746305750921,53.12391343504234,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-30,0.699999988079071,0.7099999785423279,0.5099999904632568,0.5920000076293945,700779,0.0,0.0,0.6876000046730042,0.6660499989986419,0.6333583325147629,-13.903431703592453,3.235493687675272,5.161638334191647,39.96795615274602,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-05-31,0.550000011920929,0.5899999737739563,0.550000011920929,0.550000011920929,448098,0.0,0.0,0.6742000043392181,0.6655499994754791,0.6325249994794527,-18.42183204077806,1.2996776907153624,5.221137508115072,35.86826905438082,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-01,0.550000011920929,0.6000000238418579,0.5,0.5419999957084656,734598,0.0,0.0,0.6548000037670135,0.6648499995470047,0.6317083328962326,-17.226635218328997,-1.5116185285160226,5.2463557823949305,35.129119465860384,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-02,0.5419999957084656,0.6000000238418579,0.5419999957084656,0.5899999737739563,41736,0.0,0.0,0.6417999982833862,0.6646999984979629,0.6309583326180775,-8.07105401183838,-3.4451632715998723,5.347685280560258,42.75196872858217,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-05,0.5899999737739563,0.6159999966621399,0.5019999742507935,0.5260000228881836,230776,0.0,0.0,0.6236000001430512,0.6598499983549118,0.6297249992688497,-15.651054719768851,-5.493672547129855,4.783834073768557,36.57986857132939,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-07,0.5260000228881836,0.5720000267028809,0.5239999890327454,0.5699999928474426,255050,0.0,0.0,0.6106000006198883,0.6566499978303909,0.6294749990105629,-6.6491987768142895,-7.0128679452759375,4.317089457491222,42.704179249431256,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-08,0.5699999928474426,0.578000009059906,0.5220000147819519,0.5400000214576721,173263,0.0,0.0,0.5962000012397766,0.6501499980688095,0.6292249992489815,-9.426363580214458,-8.29808459421437,3.325519304668962,39.87668173314681,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-09,0.550000011920929,0.7200000286102295,0.550000011920929,0.6299999952316284,43473,0.0,0.0,0.5920000016689301,0.6487499982118606,0.6297166660428047,6.418917813441063,-8.747591013387233,3.0225231751706745,50.471494817165166,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-12,0.6299999952316284,0.6299999952316284,0.6140000224113464,0.6140000224113464,24940,0.0,0.0,0.5844000041484833,0.6460999980568886,0.6302333330114682,5.0650270453014,-9.549604410147774,2.517585823270254,48.8242891352189,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-13,0.5699999928474426,0.6039999723434448,0.550000011920929,0.5699999928474426,281010,0.0,0.0,0.5724000036716461,0.6428499981760979,0.630808333059152,-0.41928910007139747,-10.959009831894436,1.9089261326889866,44.521140456461225,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-14,0.5699999928474426,0.593999981880188,0.5699999928474426,0.5699999928474426,7340,0.0,0.0,0.5702000021934509,0.6399999976158142,0.6311749994754792,-0.03507705107661885,-10.906249325373205,1.398185629606491,44.521140456461225,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-15,0.5580000281333923,0.5740000009536743,0.4779999852180481,0.550000011920929,359748,0.0,0.0,0.5702000021934509,0.636949998140335,0.6314916660388311,-3.542614906141079,-10.479628878525805,0.8643553660402998,42.544447168671134,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-16,0.5099999904632568,0.5559999942779541,0.47099998593330383,0.5559999942779541,290352,0.0,0.0,0.5716000020503997,0.6336499974131584,0.631808332602183,-2.7291825956064524,-9.7924714931073,0.2914910608079878,43.35694968521349,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-19,0.5559999942779541,0.5559999942779541,0.5019999742507935,0.527999997138977,147050,0.0,0.0,0.5654000043869019,0.6294499978423118,0.6312499990065893,-6.614787222805196,-10.175549078555338,-0.28514869974022555,40.48003932764944,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-20,0.5419999957084656,0.5419999957084656,0.5019999742507935,0.5220000147819519,78460,0.0,0.0,0.5650000035762787,0.6254499986767769,0.6309666658441225,-7.61061743754865,-9.665040407448757,-0.8743199072117918,39.86953956516224,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-21,0.5019999742507935,0.5239999890327454,0.4959999918937683,0.5239999890327454,204997,0.0,0.0,0.560400003194809,0.6215999990701675,0.6309749990701675,-6.495362946921696,-9.845559196735156,-1.485795794415854,40.19332206164864,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-22,0.5460000038146973,0.5479999780654907,0.5059999823570251,0.5260000228881836,17690,0.0,0.0,0.5590000033378602,0.6193499997258186,0.630899999042352,-5.903395394030317,-9.744085963457646,-1.8307179163203797,40.53814402864873,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-26,0.5040000081062317,0.550000011920929,0.5040000081062317,0.550000011920929,62926,0.0,0.0,0.5510000050067901,0.6185499995946884,0.630899999042352,-0.18148694678303326,-10.92070077312442,-1.9575209171675136,44.66132486158248,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-27,0.550000011920929,0.550000011920929,0.5099999904632568,0.5199999809265137,303634,0.0,0.0,0.5416000008583068,0.6174999997019768,0.6306249991059303,-3.9881868348527116,-12.291497794380803,-2.0812684911891375,40.84835127007542,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-28,0.5120000243186951,0.5339999794960022,0.5099999904632568,0.5299999713897705,121897,0.0,0.0,0.5375999987125397,0.6170499995350838,0.6296333322922388,-1.41369556193638,-12.875780063593817,-1.9985175675729026,42.607293070387044,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-29,0.5120000243186951,0.5720000267028809,0.5,0.5460000038146973,163047,0.0,0.0,0.5351999998092651,0.6156499996781349,0.6290416657924652,2.0179379688492225,-13.067489630622836,-2.1288996965661253,45.404639869307516,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-06-30,0.5799999833106995,0.6200000047683716,0.5440000295639038,0.5640000104904175,46586,0.0,0.0,0.536599999666214,0.6128000006079674,0.6283666660388311,5.106226396058029,-12.434725989907689,-2.4773219637818507,48.448782622961645,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-03,0.5440000295639038,0.5799999833106995,0.5320000052452087,0.578000009059906,8022,0.0,0.0,0.5388000011444092,0.6100500002503395,0.6281583329041799,7.27542832818043,-11.679370392048561,-2.882765650838328,50.74897703177674,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-04,0.5139999985694885,0.5659999847412109,0.5139999985694885,0.5320000052452087,64034,0.0,0.0,0.5392000019550324,0.6073500007390976,0.6269499997297923,-1.3353109576628097,-11.220877369084056,-3.126245952490949,43.82904009158794,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-05,0.5299999713897705,0.5600000023841858,0.5019999742507935,0.5460000038146973,195252,0.0,0.0,0.5416000008583068,0.6037500008940697,0.6258583332101504,0.8124082255202123,-10.293995849892733,-3.532481896131779,46.23203712119088,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-06,0.550000011920929,0.5619999766349792,0.550000011920929,0.5559999942779541,152038,0.0,0.0,0.5448000013828278,0.6017500013113022,0.6252416665355365,2.055798984342536,-9.464063116638458,-3.7572136473887916,47.94504645549407,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-07,0.5559999942779541,0.5559999942779541,0.5080000162124634,0.550000011920929,53433,0.0,0.0,0.5472000002861023,0.5991500020027161,0.624558333059152,0.5116980324127747,-8.670616964527406,-4.068207837686395,46.97795984563308,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-10,0.550000011920929,0.5619999766349792,0.5320000052452087,0.5600000023841858,62025,0.0,0.0,0.548199999332428,0.5966500014066696,0.623799999554952,2.1524996472322604,-8.120338885446277,-4.352356230787516,48.8304977989957,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-11,0.5400000214576721,0.5400000214576721,0.5019999742507935,0.5260000228881836,43167,0.0,0.0,0.5488000035285949,0.5935500025749206,0.6227666666110356,-4.154515396103373,-7.539381493082741,-4.6914302904338,43.29211198934907,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-12,0.5120000243186951,0.5360000133514404,0.5120000243186951,0.5360000133514404,11111,0.0,0.0,0.5494000077247619,0.5894500032067299,0.6216583331425984,-2.439023331800649,-6.794468617200393,-5.181034053392229,45.25869732453863,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-13,0.5400000214576721,0.5559999942779541,0.49799999594688416,0.527999997138977,35918,0.0,0.0,0.5476000070571899,0.5851500034332275,0.6204249997933705,-3.5792566956935583,-6.417157336703752,-5.685618144318997,43.945706360105284,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-14,0.5640000104904175,0.5640000104904175,0.5019999742507935,0.5379999876022339,62100,0.0,0.0,0.5450000047683716,0.5815000027418137,0.6194166665275892,-1.2844068082371467,-6.276869785269472,-6.121350269493707,46.05251127520745,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-17,0.5220000147819519,0.5600000023841858,0.5099999904632568,0.5199999809265137,24676,0.0,0.0,0.5392000019550324,0.5761000022292138,0.618166666229566,-3.5608347475710733,-6.405138019683592,-6.805068325170752,42.92510321942451,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-18,0.5199999809265137,0.578000009059906,0.5199999809265137,0.5479999780654907,249128,0.0,0.0,0.5407999992370606,0.5718000009655952,0.6170666659871737,1.3313570337625003,-5.421476333715488,-7.3357819368125465,48.75490200092132,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-19,0.4519999921321869,0.5260000228881836,0.4519999921321869,0.5239999890327454,87640,0.0,0.0,0.5385999977588654,0.5672000005841256,0.6154916658997536,-2.710733157606976,-5.042313609980036,-7.84603074113653,44.554085563963504,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-20,0.5220000147819519,0.5220000147819519,0.5199999809265137,0.5199999809265137,2335,0.0,0.0,0.5349999964237213,0.5627000004053115,0.6138833324114482,-2.8037412331733162,-4.922694857230847,-8.337631811093322,43.87555017428121,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-21,0.5199999809265137,0.527999997138977,0.492000013589859,0.5019999742507935,284133,0.0,0.0,0.5301999926567078,0.5581499993801117,0.6123916655778885,-5.318751187568048,-5.007615650711366,-8.85734885803699,40.85991431613737,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-24,0.5,0.5019999742507935,0.47200000286102295,0.49900001287460327,37458,0.0,0.0,0.5240999937057496,0.5538249999284744,0.6104333321253459,-4.789158773628683,-5.367220011116116,-9.273466768234657,40.361997657219014,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-25,0.49799999594688416,0.5,0.492000013589859,0.49799999594688416,17207,0.0,0.0,0.5212999910116196,0.5490249998867511,0.6086249989767869,-4.4695943730058705,-5.049862735003038,-9.792565075413364,40.18620022768739,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-26,0.49799999594688416,0.49799999594688416,0.4620000123977661,0.49399998784065247,155129,0.0,0.0,0.5170999884605407,0.5441249996423722,0.6070333321889242,-4.467221259984807,-4.96669169760509,-10.363241886521871,39.44611404335968,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-27,0.49900001287460327,0.5,0.46000000834465027,0.5,292762,0.0,0.0,0.5142999887466431,0.5418249994516373,0.605441665649414,-2.780476192794085,-5.080055503686869,-10.507480704939537,41.195524336783166,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-28,0.5,0.5,0.4749999940395355,0.4860000014305115,127229,0.0,0.0,0.5090999901294708,0.5402249991893768,0.6037166655063629,-4.53741684282585,-5.761489954483776,-10.516798681337203,38.40732234249989,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-07-31,0.4860000014305115,0.49000000953674316,0.46799999475479126,0.48899999260902405,78452,0.0,0.0,0.5059999912977219,0.5388999991118908,0.6019416652619839,-3.359683593096215,-6.1050302223767385,-10.473052421559053,39.35453866325788,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-01,0.47699999809265137,0.49399998784065247,0.47200000286102295,0.4909999966621399,183137,0.0,0.0,0.5002999931573868,0.5364249996840954,0.6001833317180475,-1.858883994092179,-6.734400251290089,-10.623142740642507,40.016823979624775,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-02,0.4749999940395355,0.49900001287460327,0.4740000069141388,0.49900001287460327,62410,0.0,0.0,0.49779999554157256,0.5357499994337559,0.5982833318412304,0.24106415102016512,-7.083528498794848,-10.452126789998772,42.71181048168256,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-03,0.47999998927116394,0.5460000038146973,0.47999998927116394,0.5,111953,0.0,0.0,0.4957999974489212,0.5339999996125698,0.5965666654209296,0.847116291385514,-7.153558462802182,-10.487791127956097,43.05620936593716,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-04,0.5,0.515999972820282,0.49300000071525574,0.515999972820282,88447,0.0,0.0,0.49719999730587006,0.5333999983966351,0.5948666649560134,3.781169673427504,-6.786651893434541,-10.332847708641287,48.401186741875605,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-07,0.5059999823570251,0.5059999823570251,0.46399998664855957,0.49000000953674316,87340,0.0,0.0,0.49629999697208405,0.529899998754263,0.5925749984880289,-1.2693909880670913,-6.340819373687273,-10.576720228440763,41.5724105663381,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-08,0.46799999475479126,0.48899999260902405,0.46799999475479126,0.4880000054836273,167445,0.0,0.0,0.49529999792575835,0.52674999833107,0.5907166649897894,-1.4738527100145968,-5.970574372084728,-10.82865448866676,41.09213728897242,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-09,0.4519999921321869,0.49900001287460327,0.4519999921321869,0.4880000054836273,169856,0.0,0.0,0.49469999969005585,0.5246999986469746,0.5888833316663901,-1.354355005180164,-5.717552703312117,-10.899159403577102,41.09213728897241,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-10,0.45100000500679016,0.4819999933242798,0.45100000500679016,0.4740000069141388,120626,0.0,0.0,0.4921000003814697,0.522299998998642,0.5869749983151754,-3.67811287407032,-5.782117303287758,-11.018356744694987,37.56863087982778,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-11,0.4869999885559082,0.5,0.46799999475479126,0.48899999260902405,115073,0.0,0.0,0.492399999499321,0.5207749985158443,0.5853999984761079,-0.6904969321190356,-5.448610071026672,-11.039460220104727,43.18937057969028,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-14,0.4970000088214874,0.5080000162124634,0.46299999952316284,0.5059999823570251,53267,0.0,0.0,0.4940999984741211,0.5195249982178212,0.5840916650990645,2.4084160938379973,-4.893893427826955,-11.054201033718321,48.813887866355394,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-15,0.49799999594688416,0.5400000214576721,0.46000000834465027,0.49799999594688416,126940,0.0,0.0,0.49479999840259553,0.5187749981880188,0.5821499983469646,0.6467254556627821,-4.621464000609761,-10.886369550614337,46.48170306859984,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-16,0.47099998593330383,1.809999942779541,0.47099998593330383,1.7949999570846558,26411344,0.0,0.0,0.6243999928236008,0.5505999967455864,0.5919416646162668,187.47597336884675,13.403559119909502,-6.984078050576271,94.27103697637207,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-17,1.6749999523162842,1.7050000429153442,1.2050000429153442,1.2200000286102295,25444478,0.0,0.0,0.6963999956846237,0.5679999977350235,0.5971916650732358,75.18667951898246,22.605633531974032,-4.888157193994401,66.09363983931462,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-18,1.1799999475479126,1.309999942779541,1.065000057220459,1.1150000095367432,5959408,0.0,0.0,0.7562999993562698,0.5827249974012375,0.6014083315928777,47.42827059180001,29.78677810787591,-3.1065971670455332,62.42434305744412,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-21,1.090000033378601,1.1799999475479126,1.0299999713897705,1.034999966621399,955573,0.0,0.0,0.8107999950647354,0.5948499962687492,0.6049333314100901,27.651698682948687,36.30326975717445,-1.6668506458119539,59.70466820822189,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-22,1.0499999523162842,1.0700000524520874,0.9620000123977661,1.0,2196665,0.0,0.0,0.8619999945163727,0.6068499967455864,0.6079749981562297,16.00928148045437,42.044986263344164,-0.18504073589457423,58.50376253726058,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-23,1.0,1.0299999713897705,0.9100000262260437,0.9200000166893005,1855379,0.0,0.0,0.90519999563694,0.6165999978780746,0.6105833316842715,1.6350001241379357,46.80505980409241,0.9853964039939305,55.743794309831635,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-24,0.9660000205039978,1.1200000047683716,0.949999988079071,0.9739999771118164,2769192,0.0,0.0,0.9551999926567077,0.6272999972105027,0.6135916650295258,1.9681725920893351,52.271639869969874,2.2341131671528247,57.2111621760742,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-25,1.0099999904632568,1.065000057220459,0.9739999771118164,1.0149999856948853,1200793,0.0,0.0,1.0077999919652938,0.6385749965906143,0.6166499982277552,0.7144268492750105,57.820146004148484,3.5555012447695273,58.340576452217775,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-28,1.0449999570846558,1.25,0.9520000219345093,1.1449999809265137,2233981,0.0,0.0,1.0716999918222427,0.6527499958872796,0.6207999979456266,6.839599670019296,64.18230541165867,5.146584737014023,61.78488482286785,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-29,1.1449999809265137,1.225000023841858,1.090000033378601,1.1649999618530273,1329089,0.0,0.0,1.138399988412857,0.668574994802475,0.6255916645129521,2.33661048057947,70.2725942882725,6.870828485700342,62.30128484037227,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-30,1.184999942779541,1.2450000047683716,1.090000033378601,1.190000057220459,917207,0.0,0.0,1.0778999984264375,0.6846749961376191,0.6306749984622002,10.399857032903773,57.43235907650709,8.562254379369595,62.97479677174752,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-08-31,1.190000057220459,1.5,1.1349999904632568,1.4700000286102295,4634041,0.0,0.0,1.1028999984264374,0.7075249969959259,0.6380083322525024,33.28497875669164,55.88141805720374,10.895886656839313,69.53877478131172,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-01,1.4800000190734863,1.9199999570846558,1.4299999475479126,1.809999942779541,5216766,0.0,0.0,1.172399991750717,0.7390249952673912,0.6475916648904483,54.38416543117772,58.64145316580582,14.118978877285345,75.27162664097722,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-04,1.8350000381469727,2.5999999046325684,1.7799999713897705,2.369999885559082,7815585,0.0,0.0,1.3058999836444856,0.7842749923467636,0.6625083307425181,81.48402750912997,66.51047099396584,18.379642331104463,81.46053880154072,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-05,2.4000000953674316,3.2799999713897705,2.1500000953674316,2.990000009536743,15468325,0.0,0.0,1.5048999845981599,0.8458749920129776,0.683099997540315,98.68430062713679,77.9104476202639,23.82886767073307,85.72136590050599,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-06,2.809999942779541,3.0899999141693115,2.2799999713897705,2.4800000190734863,8649483,0.0,0.0,1.6608999848365784,0.8944749921560288,0.6992249975601832,49.31663807062422,85.68433990906449,27.923772072957124,71.2213055917401,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-07,2.4000000953674316,2.619999885559082,2.25,2.319999933242798,2279487,0.0,0.0,1.7954999804496765,0.9392749905586243,0.7141916637619337,29.211916374499886,91.15807388652189,31.515815462068904,67.37105660170471,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-08,2.319999933242798,2.4800000190734863,2.2100000381469727,2.3399999141693115,1463433,0.0,0.0,1.9279999732971191,0.9843249887228012,0.729554163167874,21.369291834979716,95.87026595746309,34.92144084938943,67.6067931274834,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-11,2.240000009536743,2.4800000190734863,2.140000104904175,2.299999952316284,1241681,0.0,0.0,2.043499970436096,1.0288249880075455,0.7445458295444648,12.551993422610588,98.62464406056094,38.18155272416355,66.57088115440328,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-12,2.309999942779541,2.3399999141693115,2.140000104904175,2.2200000286102295,529468,0.0,0.0,2.1489999771118162,1.070624989271164,0.7589624963700772,3.3038646930948294,100.72387611415311,41.06428109316184,64.44406418300301,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-13,2.549999952316284,2.6600000858306885,2.1600000858306885,2.2300000190734863,2733028,0.0,0.0,2.2529999732971193,1.1132749900221826,0.773454163223505,-1.0208590544266207,102.37587240257928,43.93548356924152,64.59632524355447,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-14,2.240000009536743,2.3399999141693115,2.059999942779541,2.2100000381469727,765533,0.0,0.0,2.3269999742507936,1.155524991452694,0.7877916636566321,-5.027930270669236,101.38032422175083,46.67900725036645,64.00597205464118,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-15,2.2100000381469727,2.2699999809265137,2.069999933242798,2.2300000190734863,550688,0.0,0.0,2.368999981880188,1.1987249925732613,0.802362497150898,-5.86745309708202,97.62664468976642,49.39942941373797,64.3567770360134,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-18,2.25,2.25,2.069999933242798,2.0799999237060547,391798,0.0,0.0,2.3399999856948854,1.2382499903440476,0.8156958299378554,-11.111113828131979,88.97637827113705,51.80290800780297,59.6603484306983,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-19,2.0799999237060547,2.25,1.840000033378601,1.8849999904632568,848533,0.0,0.0,2.2294999837875364,1.2729249902069568,0.8273208297789096,-15.451894856667971,75.14778961367206,53.86110737078007,54.130155028386206,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-20,1.840000033378601,2.0999999046325684,1.840000033378601,2.069999933242798,198843,0.0,0.0,2.1884999752044676,1.3123249888420105,0.8405666624506315,-5.414669559253639,66.76509201700028,56.12384448081612,58.09847079083777,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-21,2.069999933242798,2.0899999141693115,1.9950000047683716,1.9950000047683716,209260,0.0,0.0,2.155999982357025,1.3496999889612198,0.852524995803833,-7.467531489153441,59.739201303273646,58.31793737479896,55.98392904769848,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-22,1.9950000047683716,2.059999942779541,1.9450000524520874,2.049999952316284,132378,0.0,0.0,2.1269999861717226,1.388799987733364,0.8648583287994067,-3.620123853128311,53.15380220035584,60.581212146189465,57.21375002089817,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-25,2.059999942779541,2.059999942779541,1.899999976158142,1.9700000286102295,181087,0.0,0.0,2.093999993801117,1.4258249886333942,0.8765249957640966,-5.921679348517936,46.86234359015873,62.66792111164544,54.81469819391295,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-26,1.9700000286102295,1.9700000286102295,1.8350000381469727,1.850000023841858,148327,0.0,0.0,2.05699999332428,1.4597999893128872,0.8869749958316485,-10.063197382314678,40.909714233693656,64.58186489734635,51.33734357191102,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-27,1.9199999570846558,1.9450000524520874,1.8300000429153442,1.8799999952316284,59760,0.0,0.0,2.021999990940094,1.4943249888718129,0.8966416622201602,-7.022749571944617,35.311930537055794,66.6579919085779,52.154522406987134,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-28,1.8700000047683716,1.8849999904632568,1.7050000429153442,1.7999999523162842,79454,0.0,0.0,1.9809999823570252,1.52682498767972,0.9058249950408935,-9.13680119398004,29.746368990692527,68.55628802899079,49.75506704138461,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-09-29,1.7999999523162842,1.9950000047683716,1.7799999713897705,1.9900000095367432,177399,0.0,0.0,1.9569999814033507,1.5636749885976315,0.915741661687692,1.6862559247306859,25.153884002357124,70.7550343091099,55.044964384032916,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-02,2.059999942779541,2.190000057220459,1.9600000381469727,2.0399999618530273,192399,0.0,0.0,1.9529999852180482,1.6024249874055385,0.927024994790554,4.454683937197562,21.87777902665636,72.85671868724316,56.34742727743249,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-03,2.0399999618530273,2.0899999141693115,1.9550000429153442,2.0,127588,0.0,0.0,1.9644999861717225,1.6402249872684478,0.9376916612188021,1.8070763083820323,19.77015357163329,74.92157124832485,54.975192436518384,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-04,2.0,2.059999942779541,1.8799999952316284,2.059999942779541,213841,0.0,0.0,1.9634999871253966,1.6795249857008456,0.9490249941746394,4.914690923702131,16.908054589378533,76.97373578253513,56.67940855984846,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-05,2.059999942779541,2.1700000762939453,1.9299999475479126,1.9950000047683716,80492,0.0,0.0,1.9634999871253966,1.7175499856472016,0.9599499940872193,1.6042789839327474,14.31981622272943,78.92077673070419,54.28235216137715,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-06,1.9950000047683716,2.0999999046325684,1.940000057220459,2.009999990463257,45803,0.0,0.0,1.959499990940094,1.7555749855935574,0.9710999940832455,2.577188045759304,11.615852755932833,80.78210238801262,54.75786106948886,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-09,1.9700000286102295,2.0799999237060547,1.8350000381469727,1.899999976158142,95948,0.0,0.0,1.9524999856948853,1.7904249854385852,0.9811999936898549,-2.688860943476968,9.052320067830037,82.47299194383365,50.60139845127037,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-10,1.875,1.875,1.850000023841858,1.875,43086,0.0,0.0,1.9549999833106995,1.8248499855399132,0.9910249938567479,-4.092070792513425,7.1320929830996045,84.13763495895182,49.67845097776212,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-11,1.7649999856948853,1.875,1.7649999856948853,1.8650000095367432,91758,0.0,0.0,1.953499984741211,1.8265999868512153,1.0008833274245261,-4.530328942704943,6.9473337787958815,82.49879249676623,49.29116814070008,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-12,1.8300000429153442,2.0999999046325684,1.8300000429153442,1.9700000286102295,39501,0.0,0.0,1.9704999923706055,1.8453499868512153,1.0116499945521356,-0.025372431479915733,6.781911637961856,82.40992406352599,53.39915001861288,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-13,1.9700000286102295,1.9950000047683716,1.8049999475479126,1.975000023841858,61627,0.0,0.0,1.968999993801117,1.8668499872088433,1.022974994778633,0.3047247363956598,5.471784411826237,82.4922404494179,53.591948294032505,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-16,1.975000023841858,1.975000023841858,1.6349999904632568,1.9199999570846558,71571,0.0,0.0,1.9569999933242799,1.8889749869704247,1.034124994277954,-1.8906508107224667,3.60115972011652,82.66408774785909,51.08810353937578,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-17,1.875,1.9199999570846558,1.784999966621399,1.8949999809265137,40718,0.0,0.0,1.9464999914169312,1.9113499864935874,1.0452333276470502,-2.6457750175960038,1.83901457983774,82.86347516264844,49.94583506180448,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-18,1.934999942779541,1.940000057220459,1.8200000524520874,1.8799999952316284,13095,0.0,0.0,1.92849999666214,1.9353499859571457,1.0563333277901015,-2.5149080380842928,-0.3539405970346015,83.21394724958532,49.23453283896443,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-19,1.8799999952316284,1.9249999523162842,1.7799999713897705,1.8550000190734863,25680,0.0,0.0,1.9144999980926514,1.9573749870061874,1.0667749946316083,-3.1078599675342264,-2.1904330645970647,83.4852707324783,48.00738642288474,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-20,1.7599999904632568,1.9149999618530273,1.7400000095367432,1.850000023841858,87368,0.0,0.0,1.8985000014305116,1.9782499879598618,1.0765416617194812,-2.5546472242354032,-4.03134017514112,83.75972415225881,47.75104187044548,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-23,1.850000023841858,1.8949999809265137,1.7549999952316284,1.8250000476837158,67181,0.0,0.0,1.891000008583069,1.9952499896287919,1.086016661922137,-3.4902147329341924,-5.224908236442001,83.72185801435184,46.41646743234034,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-24,1.7699999809265137,1.850000023841858,1.7649999856948853,1.850000023841858,42968,0.0,0.0,1.8885000109672547,2.0123749911785125,1.0960999955733617,-2.0386543236331693,-6.155660885981917,83.5941063137998,47.982126606556115,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-25,2.049999952316284,2.0999999046325684,1.899999976158142,2.0199999809265137,231702,0.0,0.0,1.9040000081062316,2.033124989271164,1.1071833287676176,6.092435521345333,-6.351059666588488,83.6303831935577,57.15073046492414,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-26,2.0199999809265137,2.069999933242798,1.9600000381469727,2.0,82680,0.0,0.0,1.9070000052452087,2.0463749885559084,1.1185499956210454,4.876769507026457,-6.810823240615063,82.94890676028412,55.902352334871985,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-27,2.0,2.0,1.8350000381469727,1.8700000047683716,65548,0.0,0.0,1.89650000333786,2.047874990105629,1.1286833291252454,-1.397310757861756,-7.3918079716360445,81.43928746540247,48.48823906617935,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-30,1.8650000095367432,2.009999990463257,1.8250000476837158,1.899999976158142,101370,0.0,0.0,1.8945000052452088,2.0361249923706053,1.1390166620413462,0.29031253088972325,-6.9556136119377605,78.76165118791687,50.13190699706052,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-10-31,1.9500000476837158,1.9500000476837158,1.725000023841858,1.7999999523162842,148029,0.0,0.0,1.8850000023841857,2.006374990940094,1.1485999951759973,-4.509286470047311,-6.049466779838482,74.68004521736586,44.97975446472499,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-01,1.7999999523162842,1.9850000143051147,1.725000023841858,1.7450000047683716,201903,0.0,0.0,1.8715000033378602,1.9879999905824661,1.1573083286484083,-6.759283908302064,-5.860160351936044,71.77790407023184,42.3988304485701,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-02,1.7350000143051147,1.909999966621399,1.725000023841858,1.7949999570846558,189017,0.0,0.0,1.865499997138977,1.9748749911785126,1.1664333283901214,-3.7791498344917476,-5.538324933380507,69.30886173358745,45.462522992197435,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-03,1.9500000476837158,1.9500000476837158,1.7549999952316284,1.9049999713897705,44897,0.0,0.0,1.8709999918937683,1.9639999926090241,1.1766083280245463,1.817208960091361,-4.735234270124025,66.92045652153938,51.565934318281506,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-06,1.840000033378601,1.850000023841858,1.75,1.8250000476837158,48477,0.0,0.0,1.8709999918937683,1.9521249949932098,1.1856833284099897,-2.458575329200978,-4.155727902030355,64.64134632060858,47.41034847239559,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-07,1.7699999809265137,1.8200000524520874,1.690000057220459,1.7899999618530273,132601,0.0,0.0,1.8649999856948853,1.9413749933242799,1.1945999945203463,-4.021449030409164,-3.9340677556897496,62.51255669089279,45.67605659680779,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-08,1.7899999618530273,1.8799999952316284,1.7699999809265137,1.8700000047683716,39712,0.0,0.0,1.849999988079071,1.9323749929666518,1.2042833278576532,1.0810819901716564,-4.262889200460817,60.4585024359865,50.163532099608375,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-09,1.8650000095367432,1.8650000095367432,1.7400000095367432,1.7799999713897705,83527,0.0,0.0,1.8279999852180482,1.921624991297722,1.2132833277185757,-2.6258213466315823,-4.872178833209616,58.38221356845743,45.59988853101266,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-10,1.7899999618530273,1.8300000429153442,1.7649999856948853,1.8200000524520874,31077,0.0,0.0,1.8229999899864198,1.911374992132187,1.2227499946951865,-0.1645604800225321,-4.623634949162052,56.31772647103257,47.86983488788281,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-13,1.8200000524520874,1.9450000524520874,1.815000057220459,1.8650000095367432,108248,0.0,0.0,1.8194999933242797,1.9059999942779542,1.2326916615168253,2.5006879021380817,-4.538300168591716,54.62098542409413,50.378384063879274,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-14,1.8650000095367432,2.240000009536743,1.809999942779541,2.059999942779541,459707,0.0,0.0,1.8454999923706055,1.9103749930858611,1.244108327726523,11.622863792776467,-3.3959301681635794,53.55375014464136,59.4781432942544,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-15,2.059999942779541,2.190000057220459,1.9500000476837158,1.9950000047683716,159556,0.0,0.0,1.8704999923706054,1.9084999948740005,1.2549833277861278,6.655975028365507,-1.9910926175246781,52.07373298263003,55.80454445723313,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-16,2.0,2.25,1.9600000381469727,2.180000066757202,296316,0.0,0.0,1.90900000333786,1.9131249964237214,1.2682166616121928,14.195917388449569,-0.21561545082377517,50.85158982154538,62.83947456380278,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-17,2.4000000953674316,2.430000066757202,2.200000047683716,2.299999952316284,203532,0.0,0.0,1.9485000014305114,1.9193749964237212,1.2827999944488206,18.039515043762663,1.517421299175897,49.6238700288128,66.55797919183931,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-20,2.440000057220459,2.440000057220459,2.0199999809265137,2.119999885559082,253504,0.0,0.0,1.977999985218048,1.9231249928474425,1.2959499935309091,7.178963670486597,2.8534282781773754,48.39499999592962,57.2963029047701,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-21,2.119999885559082,2.180000066757202,2.0399999618530273,2.0399999618530273,101062,0.0,0.0,2.002999985218048,1.9278749912977218,1.3080333267649016,1.8472280033966897,3.8967772422711344,47.387299073323,53.718511393925816,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-22,2.0399999618530273,2.25,2.0,2.0999999046325684,72077,0.0,0.0,2.025999975204468,1.9333749890327454,1.3211499924461048,3.6525138368095087,4.790844336827912,46.34030958537176,55.94065641795038,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-23,2.109999895095825,2.200000047683716,2.009999990463257,2.069999933242798,38900,0.0,0.0,2.0549999713897704,1.9401249885559082,1.3336499919493994,0.7299251611611044,5.921009394315726,45.474824749184975,54.530841926331036,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-24,2.119999885559082,2.119999885559082,1.9800000190734863,2.049999952316284,115175,0.0,0.0,2.0779999613761904,1.9416249871253968,1.3462333247065543,-1.3474499316815536,7.023754594995127,44.22648373740289,53.56171138205143,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-27,2.049999952316284,2.049999952316284,1.8350000381469727,1.8600000143051147,227208,0.0,0.0,2.0774999618530274,1.937124988436699,1.3564833248655002,-10.469311746889923,7.246562521998852,42.80492453740789,45.32126620292021,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-28,1.8650000095367432,1.9299999475479126,1.7450000047683716,1.8899999856948853,220176,0.0,0.0,2.0604999661445618,1.934374988079071,1.3671166578928629,-8.274689796219802,6.520192767315451,41.49304500908676,46.71522967146144,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-29,1.8899999856948853,2.0,1.6349999904632568,1.6349999904632568,963317,0.0,0.0,2.0244999647140505,1.923749989271164,1.3759916578729947,-19.239317413661126,5.237165744237732,39.808259611464,37.87622033184915,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-11-30,1.6799999475479126,2.0299999713897705,1.6799999475479126,1.840000033378601,444532,0.0,0.0,1.9904999613761902,1.9198749899864196,1.3865749915440877,-7.560910872539613,3.6786234394495763,38.46167727635487,46.62039671265055,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-01,1.8949999809265137,1.909999966621399,1.75,1.8600000143051147,139558,0.0,0.0,1.9464999675750732,1.9161249905824662,1.3974916582306227,-4.44387129262165,1.5852294157164306,37.11173009851737,47.398292100773446,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-04,1.8600000143051147,1.8700000047683716,1.7300000190734863,1.7649999856948853,96625,0.0,0.0,1.9109999775886535,1.9127499908208847,1.407566658159097,-7.639978733960771,-0.0914920005557122,35.890544133980676,44.11006086930501,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-05,1.715000033378601,2.0,1.715000033378601,1.850000023841858,313786,0.0,0.0,1.8919999837875365,1.9121249914169312,1.4185833250482878,-2.2198710520916705,-1.052494356787916,34.79116507673904,47.612022301129365,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-06,1.850000023841858,1.8949999809265137,1.7549999952316284,1.8250000476837158,17754,0.0,0.0,1.8644999980926513,1.9111249923706055,1.4294416586558023,-2.1185277795303414,-2.4396622127849117,33.69730627325928,46.68548113796336,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-07,1.8300000429153442,1.8949999809265137,1.7799999713897705,1.850000023841858,51196,0.0,0.0,1.8425000071525575,1.908124992251396,1.4404916589458783,0.40705653515253704,-3.4392393247471555,32.46345304406151,47.77986767394681,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-08,1.8899999856948853,1.8899999856948853,1.774999976158142,1.840000033378601,66208,0.0,0.0,1.821500015258789,1.9047499924898148,1.4514416590332986,1.0156474315035167,-4.3706511384312785,31.23159175122702,47.36108226691554,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-11,1.9199999570846558,1.9199999570846558,1.809999942779541,1.8250000476837158,60385,0.0,0.0,1.8180000185966492,1.9023749947547912,1.4620666593313216,0.38504009986040116,-4.435244175873835,30.115476104546783,46.699874039538315,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-12,1.8250000476837158,1.8550000190734863,1.7799999713897705,1.7949999570846558,66439,0.0,0.0,1.8085000157356261,1.8998749941587447,1.4726916591326396,-0.7464782158422643,-4.80952582164907,29.006977283873546,45.33660360151972,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-13,1.7949999570846558,1.8849999904632568,1.7949999570846558,1.8700000047683716,64227,0.0,0.0,1.8320000171661377,1.8996249943971635,1.4838583260774612,2.0742351116903834,-3.5599119526475924,28.019296789523708,49.319770784610704,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-14,1.8450000286102295,1.9199999570846558,1.7649999856948853,1.815000057220459,135399,0.0,0.0,1.8295000195503235,1.8986249953508376,1.4944333265225092,-0.7925642074291137,-3.640791413248032,27.046483884889494,46.63603964730813,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-15,1.8250000476837158,1.8849999904632568,1.559999942779541,1.7799999713897705,174461,0.0,0.0,1.821500015258789,1.8968749940395355,1.5045666595300038,-2.2783444151178007,-3.9736397505156584,26.07450670428128,44.959436294654324,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-18,1.2400000095367432,1.5399999618530273,1.184999942779541,1.375,568730,0.0,0.0,1.7825000166893006,1.8856249928474427,1.5112083261211713,-22.861150792366587,-5.469007705631608,24.775979608800146,31.04930747247947,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-19,1.375,1.5950000286102295,1.3600000143051147,1.3600000143051147,57004,0.0,0.0,1.7335000157356262,1.873374992609024,1.5181083261966706,-21.546005078748927,-7.466469736451206,23.401931224658117,30.670815946810663,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-20,1.3600000143051147,1.3949999809265137,1.2649999856948853,1.375,181583,0.0,0.0,1.6885000109672545,1.8572499930858613,1.5250166594982146,-18.566775773230027,-9.08601333944414,21.785554375318323,31.569156119418395,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-21,1.3799999952316284,1.3799999952316284,1.2350000143051147,1.350000023841858,198637,0.0,0.0,1.6385000109672547,1.8409999936819077,1.5316333264112472,-17.607566993855972,-10.999455915785376,20.19848105522319,30.85163231757616,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-22,1.350000023841858,1.4950000047683716,1.2400000095367432,1.4950000047683716,142106,0.0,0.0,1.6040000081062318,1.8316249936819076,1.5395083263516427,-6.795511395698273,-12.427488506700662,18.9746727789728,39.44799796724449,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-27,1.4950000047683716,1.4950000047683716,1.2599999904632568,1.3600000143051147,181078,0.0,0.0,1.5575000047683716,1.818124994635582,1.5461749931176503,-12.680577197983936,-14.334822448191966,17.58856550703758,35.07587885653081,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-28,1.399999976158142,2.0,1.3250000476837158,1.6100000143051147,339286,0.0,0.0,1.5390000104904176,1.8133749961853027,1.555208326379458,4.613385531561649,-15.130625837020622,16.60013423454718,46.828547601476906,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2023-12-29,1.6100000143051147,1.7350000143051147,1.4149999618530273,1.7350000143051147,130321,0.0,0.0,1.5255000114440918,1.8131249964237213,1.565199993054072,13.733202313299426,-15.863494549297611,15.839829061453633,51.55102310867921,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-02,1.7350000143051147,1.774999976158142,1.5299999713897705,1.7000000476837158,173397,0.0,0.0,1.5140000104904174,1.810749998688698,1.574966660141945,12.2853392275109,-16.38823627851331,14.97068760334919,50.20642411544203,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-03,1.7000000476837158,1.7999999523162842,1.4700000286102295,1.774999976158142,562573,0.0,0.0,1.5135000109672547,1.807499998807907,1.5852749933799108,17.27783041268475,-16.265559503986328,14.01807297509928,53.033402538053664,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-04,1.7000000476837158,1.8450000286102295,1.6150000095367432,1.7350000143051147,140061,0.0,0.0,1.549500012397766,1.805249997973442,1.5953999936580658,11.971603770450939,-14.167012095985523,13.153441466062352,51.35866664107028,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-05,1.625,1.8600000143051147,1.600000023841858,1.6399999856948853,165809,0.0,0.0,1.577500009536743,1.8014999985694886,1.604499993721644,3.961963599385096,-12.434082109942631,12.277968564580817,47.52047665423397,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-08,1.6549999713897705,1.7999999523162842,1.5499999523162842,1.565000057220459,141122,0.0,0.0,1.5965000152587892,1.7938749998807908,1.613174994289875,-1.9730634348427547,-11.002716724137294,11.20151293136431,44.68149724891063,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-09,1.565000057220459,1.6399999856948853,1.565000057220459,1.5850000381469727,60567,0.0,0.0,1.6200000166893005,1.7890000015497207,1.6220499947667122,-2.160492480355355,-9.446617368028175,10.292531507761558,45.61457407541825,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-10,1.5850000381469727,1.590000033378601,1.5199999809265137,1.5850000381469727,65185,0.0,0.0,1.6290000200271606,1.783125001192093,1.6310749952991803,-2.7010424394871597,-8.643532060954415,9.32207325421127,45.61457407541825,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-11,1.5149999856948853,1.6299999952316284,1.2999999523162842,1.3700000047683716,449651,0.0,0.0,1.6300000190734862,1.7707500010728836,1.6383333285649617,-15.950920936363064,-7.948608324953724,8.082401193895471,37.688861513872574,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-12,1.3700000047683716,1.399999976158142,1.1200000047683716,1.2999999523162842,1159631,0.0,0.0,1.5990000128746034,1.751750001311302,1.6450166615347068,-18.699190628572392,-8.71985091036707,6.488283205412591,35.52460622247625,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-15,1.0850000381469727,1.149999976158142,1.0449999570846558,1.0800000429153442,1362843,0.0,0.0,1.5335000157356262,1.7288750022649766,1.649899995326996,-29.572870438004934,-11.300700529152898,4.786654170656476,29.74366258685366,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-16,1.1050000190734863,1.2000000476837158,0.9559999704360962,1.0449999570846558,1779161,0.0,0.0,1.4680000066757202,1.7004999995231629,1.6544416616360347,-28.814717143560937,-13.672448862842575,2.78392033730475,28.936887336916996,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-17,1.0449999570846558,1.0800000429153442,0.9900000095367432,1.0800000429153442,284884,0.0,0.0,1.3985000133514405,1.6700000017881393,1.6593916619817415,-22.774398812684012,-16.257484320119307,0.6392908949372909,30.953779664760347,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-18,1.0800000429153442,1.0950000286102295,0.9679999947547913,1.034999966621399,646477,0.0,0.0,1.328500008583069,1.6428750038146973,1.663941661765178,-22.092588638723967,-19.135661234218112,-1.2660695043919035,29.78336157460697,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-19,1.0299999713897705,1.0449999570846558,0.949999988079071,0.9819999933242798,383524,0.0,0.0,1.2627000093460083,1.6164250046014785,1.6680333284040292,-22.23014286402927,-21.88316774663352,-3.0939623881454086,28.420337119055787,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-22,0.9520000219345093,1.0700000524520874,0.9520000219345093,1.0549999475479126,326659,0.0,0.0,1.2116999983787538,1.5903000056743621,1.6726666611929735,-12.932248167079702,-23.806829274018906,-4.92427196820352,32.97050579913319,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-23,1.0549999475479126,1.0549999475479126,1.0,1.0449999570846558,182773,0.0,0.0,1.157699990272522,1.5646750062704087,1.6772083275020122,-9.73482198625023,-26.01019472842227,-6.709561322009863,32.66418858483621,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-24,1.0399999618530273,1.0499999523162842,1.0099999904632568,1.0499999523162842,58921,0.0,0.0,1.1041999816894532,1.5396750062704085,1.6816583273311456,-4.908533804740845,-28.283567818368166,-8.443054023112406,32.99936956835148,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-25,1.0499999523162842,1.0499999523162842,1.0049999952316284,1.0499999523162842,59884,0.0,0.0,1.0721999764442445,1.5194250047206879,1.6863249935209752,-2.0705115291629292,-29.433833646738993,-9.897261170980288,32.9993695683515,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-26,1.0499999523162842,1.059999942779541,1.0099999904632568,1.0499999523162842,69017,0.0,0.0,1.0471999764442443,1.4984250038862228,1.6910083264112472,0.26737738111369386,-30.11328736985228,-11.388667904062634,32.9993695683515,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-29,1.0499999523162842,1.0499999523162842,1.0049999952316284,1.0499999523162842,61399,0.0,0.0,1.0441999673843383,1.4838000029325484,1.6956916593015194,0.5554477219985482,-29.626636654494853,-12.495883624045915,32.99936956835148,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-30,1.0499999523162842,1.0499999523162842,1.0,1.0299999713897705,42947,0.0,0.0,1.04269996881485,1.4635500013828278,1.7003249923388164,-1.2179915416622158,-28.75542565476682,-13.92527852162556,32.13865395441795,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-01-31,1.0299999713897705,1.0299999713897705,0.9819999933242798,1.0199999809265137,76465,0.0,0.0,1.0366999626159668,1.4425500005483627,1.7047499922414622,-1.6108789709332123,-28.1342094054361,-15.380553916199183,31.693531644673513,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-01,1.0199999809265137,1.0199999809265137,0.8500000238418579,0.9300000071525574,633667,0.0,0.0,1.0261999666690826,1.4216750010848045,1.708283325781425,-9.37438731641927,-27.817541569905636,-16.777563789982928,27.942548046092696,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-02,0.9300000071525574,0.9520000219345093,0.7699999809265137,0.8299999833106995,3356232,0.0,0.0,1.0109999656677247,1.3961750000715256,1.71104999234279,-17.90306513388277,-27.587876475661616,-18.402442575049125,24.476278584105927,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-05,0.8299999833106995,0.878000020980835,0.7720000147819519,0.8100000023841858,240487,0.0,0.0,0.9864999711513519,1.3707999989390374,1.7028416593869526,-17.89153308957238,-28.03472629742657,-19.49926809797777,23.839329793005533,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-06,0.8100000023841858,0.8679999709129333,0.7559999823570251,0.8199999928474426,275674,0.0,0.0,0.9639999747276307,1.345049998164177,1.699508325755596,-14.937757848061553,-28.329803647197604,-20.856521984605635,24.891779353805134,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-07,0.8960000276565552,0.9160000085830688,0.828000009059906,0.9160000085830688,390266,0.0,0.0,0.950599980354309,1.3219499975442885,1.6978499924143156,-3.639803543688696,-28.091078927328216,-22.13976479367905,34.28077937927948,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-08,0.9399999976158142,0.9399999976158142,0.8059999942779541,0.8939999938011169,245420,0.0,0.0,0.9349999845027923,1.2986749961972237,1.6966749926408131,-4.3850258161745375,-28.003543054216294,-23.45764499210994,33.25483683462805,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-09,0.8700000047683716,0.8960000276565552,0.8700000047683716,0.8960000276565552,43443,0.0,0.0,0.9195999920368194,1.276199997961521,1.6958083262046177,-2.566329337171126,-27.94232929746906,-24.743853521595835,33.44983053299319,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-12,0.8960000276565552,0.9340000152587891,0.8960000276565552,0.8999999761581421,214390,0.0,0.0,0.9045999944210052,1.2519499972462653,1.6956416592001915,-0.5085140715490971,-27.744718526241147,-26.166593604642195,33.865959140155084,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-13,0.8999999761581421,0.9079999923706055,0.8799999952316284,0.8899999856948853,52766,0.0,0.0,0.8905999958515167,1.228824995458126,1.694941659271717,-0.0673714528886552,-27.52426105073762,-27.500454736233937,33.30527115453006,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-14,0.9300000071525574,0.9300000071525574,0.8379999995231628,0.9259999990463257,113758,0.0,0.0,0.8811999976634979,1.20747499614954,1.6941999927163125,5.083976566229576,-27.0212633409789,-28.72889851607223,37.32798628281626,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-15,0.9259999990463257,0.9259999990463257,0.8999999761581421,0.9200000166893005,47609,0.0,0.0,0.8801999986171722,1.1960999965667725,1.6923249930143356,4.521701674012229,-26.41083511883156,-29.32208638978362,36.92820909504417,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-16,0.9259999990463257,0.9279999732971191,0.871999979019165,0.8999999761581421,102966,0.0,0.0,0.8871999979019165,1.1845999956130981,1.6901166598002115,1.4427387608764033,-25.10552075067839,-29.910163967431124,35.56103619956619,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-19,0.8999999761581421,0.9259999990463257,0.8500000238418579,0.9259999990463257,120625,0.0,0.0,0.8987999975681304,1.1733749955892563,1.6879166593154271,3.0262574045160067,-23.400447346607827,-30.483831111356817,38.73641220254889,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-20,0.871999979019165,0.9020000100135803,0.8679999709129333,0.8700000047683716,142902,0.0,0.0,0.9037999987602234,1.161374995112419,1.682916659116745,-3.739764775195461,-22.178452044876583,-30.990344125421505,34.76300678900556,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-21,0.9279999732971191,0.9279999732971191,0.8700000047683716,0.9200000166893005,82552,0.0,0.0,0.9041999995708465,1.1469999954104424,1.675499993065993,1.7474029115188083,-21.168264761214086,-31.542823028512814,40.619702534602155,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-22,0.9200000166893005,0.9300000071525574,0.8539999723434448,0.8999999761581421,78159,0.0,0.0,0.9047999978065491,1.135499994456768,1.6632499938209853,-0.5305063726838395,-20.317040755300724,-31.73004667517339,39.10731805559443,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-23,0.8920000195503235,0.9259999990463257,0.8320000171661377,0.9259999990463257,290233,0.0,0.0,0.9077999949455261,1.1183999940752982,1.646049993733565,2.004847345465308,-18.83047212494827,-32.055526968622196,42.12414521508684,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-26,0.9240000247955322,0.9240000247955322,0.8999999761581421,0.8999999761581421,58390,0.0,0.0,0.9077999949455261,1.097524993121624,1.6328833267092704,-0.8592221668663991,-17.286622114770665,-32.7860738627632,39.99047836724603,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-27,0.8999999761581421,0.9359999895095825,0.878000020980835,0.9359999895095825,190217,0.0,0.0,0.9123999953269959,1.0784249916672706,1.621349993844827,2.586584206867362,-15.395136205402297,-33.48598416373249,44.20460407686053,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-28,0.9359999895095825,1.3949999809265137,0.9359999895095825,1.0399999618530273,164865,0.0,0.0,0.923799991607666,1.0600499913096428,1.610516660908858,12.57847708389144,-12.853167380686099,-34.17950791571271,54.20884544072639,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-02-29,1.0399999618530273,1.0399999618530273,0.9100000262260437,0.9559999704360962,173921,0.0,0.0,0.9273999869823456,1.0405749902129173,1.5993166610598564,3.0838887055424373,-10.876198668527907,-34.93627525124791,46.89503991195182,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-01,0.9399999976158142,1.0099999904632568,0.921999990940094,0.9700000286102295,211297,0.0,0.0,0.9343999922275543,1.0238249912858008,1.5888999943931899,3.809935432234625,-8.734402834408202,-35.563912461538806,48.150641680619806,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-04,0.9620000123977661,0.9620000123977661,0.8740000128746033,0.9419999718666077,166621,0.0,0.0,0.9359999895095825,1.0082499891519547,1.5781666606664657,0.6410237632768392,-7.165881519437669,-36.112578330214696,45.81739334802492,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-05,0.9419999718666077,0.9419999718666077,0.8659999966621399,0.8659999966621399,92506,0.0,0.0,0.9355999886989593,0.9902749881148338,1.5669666603207588,-7.439075767156093,-5.521193615114744,-36.80305949125145,40.132821029749906,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-06,0.9240000247955322,0.9240000247955322,0.8420000076293945,0.8740000128746033,55300,0.0,0.0,0.9309999883174896,0.9724999874830246,1.5556666602691014,-6.122446418704813,-4.267352154208571,-37.48660864694496,40.9631547218242,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-07,0.8420000076293945,0.8960000276565552,0.8420000076293945,0.8960000276565552,37240,0.0,0.0,0.9305999934673309,0.9606499880552292,1.5457999944686889,-3.7180277298154074,-3.128089831004155,-37.85418608534691,43.292434510559154,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-08,0.8960000276565552,0.921999990940094,0.8579999804496765,0.8999999761581421,14068,0.0,0.0,0.9279999911785126,0.9506499886512756,1.5375916610161464,-3.017243026566405,-2.382580102367372,-38.17279237694222,43.72715836645118,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-11,0.8999999761581421,0.9079999923706055,0.8299999833106995,0.9020000100135803,70186,0.0,0.0,0.9281999945640564,0.9461999878287315,1.5278583283225695,-2.822665880619979,-1.902345539654897,-38.070175075226956,43.95849790667116,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-12,0.8920000195503235,1.0,0.878000020980835,0.9259999990463257,111874,0.0,0.0,0.9271999955177307,0.9432249888777733,1.5189499949415526,-0.1294215355053957,-1.6989576770128567,-37.90282813661239,46.785581942495725,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-13,0.9139999747276306,0.972000002861023,0.8980000019073486,0.972000002861023,78232,0.0,0.0,0.9203999996185303,0.9405249878764153,1.5099666620294252,5.606258503246293,-2.13976114588137,-37.7122017639561,51.80404832227625,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-14,0.9559999704360962,1.2200000286102295,0.9559999704360962,1.149999976158142,345988,0.0,0.0,0.9398000001907348,0.9433999881148338,1.5031333282589912,22.366458387395895,-0.3815971983731664,-37.23777057039047,65.40123481093772,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-15,1.149999976158142,1.215000033378601,1.0,1.1649999618530273,325601,0.0,0.0,0.9592999935150146,0.9479749873280525,1.4974249944090843,21.44271549343998,1.1946524263137541,-36.69299024208264,66.2649594746164,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-18,1.1649999618530273,1.2100000381469727,1.090000033378601,1.0950000286102295,62645,0.0,0.0,0.9745999991893768,0.9489749893546104,1.4908833280205727,12.35378919772167,2.7002829497322884,-36.348138615611674,58.87809794935293,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-19,1.024999976158142,1.190000057220459,1.024999976158142,1.1749999523162842,59781,0.0,0.0,1.0054999947547913,0.9522249892354011,1.4856749946872394,16.85728080016831,5.59479178992855,-35.90623840068998,63.83932577502335,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-20,1.1799999475479126,1.2799999713897705,0.9639999866485596,1.1100000143051147,315287,0.0,0.0,1.0290999948978423,0.953724990785122,1.4783416613936424,7.861239899753696,7.903222086135169,-35.48683530395544,57.74356871207998,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-21,1.1150000095367432,1.1649999618530273,1.0099999904632568,1.125,266631,0.0,0.0,1.051999992132187,0.9555999919772148,1.470716661711534,6.939164297887214,10.08790298914849,-35.02487482088198,58.72307952220815,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-22,1.1449999809265137,1.1699999570846558,0.9919999837875366,1.1699999570846558,86921,0.0,0.0,1.0789999902248382,0.9585999920964241,1.4637999946872393,8.43373194478485,12.559983217306684,-34.5129119022,61.5989261698027,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-25,1.1699999570846558,1.1950000524520874,1.065000057220459,1.1699999570846558,58111,0.0,0.0,1.1057999849319458,0.9615999922156334,1.456383328139782,5.80574905295021,14.99583963016259,-33.97342762472627,61.5989261698027,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-26,1.1399999856948853,1.184999942779541,1.090000033378601,1.1799999475479126,126790,0.0,0.0,1.1311999797821044,0.9653499916195869,1.4495916609962782,4.31400005640101,17.180296224405375,-33.40538459250523,62.27630177216363,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-27,1.2000000476837158,1.2000000476837158,1.0,1.0449999570846558,380743,0.0,0.0,1.1384999752044678,0.9659749910235405,1.4415499940514565,-8.212562156887177,17.860191597519627,-32.99053137181313,49.565230664168574,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-03-28,1.0099999904632568,1.0800000429153442,1.0099999904632568,1.0299999713897705,27682,0.0,0.0,1.1264999747276305,0.9684749901294708,1.43429999401172,-8.56635645830282,16.316888531838504,-32.477515570459026,48.38355338569424,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-02,1.0099999904632568,1.218000054359436,0.9739999771118164,1.0579999685287476,52951,0.0,0.0,1.1157999753952026,0.974174989759922,1.4274916604161263,-5.180140539614458,14.537941039749233,-31.756169456293605,50.74419988215174,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-03,1.0520000457763672,1.2940000295639038,1.003999948501587,1.1799999475479126,148232,0.0,0.0,1.1242999672889709,0.9834249883890152,1.4217833265662194,4.954192108824065,14.324933834631171,-30.831585234291165,59.44688920699533,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-04,1.1799999475479126,1.2680000066757202,1.1019999980926514,1.1200000047683716,57696,0.0,0.0,1.1187999725341797,0.9909249886870384,1.414699993034204,0.10726065996173313,12.904607846914216,-29.955114613259187,54.36001033876298,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-05,1.1200000047683716,1.1200000047683716,1.034000039100647,1.0759999752044678,56632,0.0,0.0,1.115399968624115,0.9949249878525734,1.4072083259622257,-3.532364580236491,12.108951151339795,-29.297960401686773,50.91897798275691,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-08,1.0800000429153442,1.1979999542236328,1.031999945640564,1.0980000495910645,280242,0.0,0.0,1.1126999735832215,1.000024989247322,1.4003583267331123,-1.3211040119664013,11.267216874320836,-28.587921380074594,52.536768889248464,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-09,1.1180000305175781,1.1180000305175781,1.0520000457763672,1.1039999723434448,220374,0.0,0.0,1.1060999751091003,1.0052249878644943,1.39376665999492,-0.18985650600420084,10.035065628333152,-27.8770961655692,52.99184931092063,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-10,1.0959999561309814,1.0959999561309814,1.031999945640564,1.093999981880188,21631,0.0,0.0,1.0984999775886535,1.0100749880075455,1.3872166598836582,-0.4096491397608899,8.75429949567739,-27.1869335758801,52.09531253315492,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-11,1.093999981880188,1.590000033378601,1.034000039100647,1.350000023841858,491056,0.0,0.0,1.115499985218048,1.0215749889612198,1.3830083265900612,21.02196698621846,9.194136237843404,-26.13385116198033,67.33238652501628,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-12,1.399999976158142,1.4500000476837158,1.2079999446868896,1.2599999904632568,403826,0.0,0.0,1.1369999885559081,1.029924988746643,1.3780916596452395,10.817942229143709,10.396388181586786,-25.264405924075078,60.09548404577198,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-15,1.2599999904632568,1.4980000257492065,1.149999976158142,1.3200000524520874,187560,0.0,0.0,1.16599999666214,1.0399249896407128,1.3738833263516426,13.20755199234966,12.123471238534737,-24.30761989067577,62.95414131630821,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-16,1.2000000476837158,1.399999976158142,1.2000000476837158,1.3960000276565552,145885,0.0,0.0,1.1998000025749207,1.052324990928173,1.3700999930500983,16.352727509631997,14.014207865259523,-23.193562786209405,66.25201713180289,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-17,1.2039999961853027,1.4819999933242798,1.2039999961853027,1.350000023841858,151217,0.0,0.0,1.2168000102043153,1.0629249915480614,1.364516660074393,10.946746591099778,14.476564186542246,-22.102454103410427,62.618506480456276,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-18,1.25600004196167,1.2999999523162842,1.1699999570846558,1.2519999742507935,145172,0.0,0.0,1.2300000071525574,1.0724749907851219,1.3582833265264829,1.788615200837749,14.687989717328225,-21.041879124899094,55.619913277385116,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-19,1.25,1.3480000495910645,1.1380000114440918,1.3480000495910645,146597,0.0,0.0,1.257200014591217,1.083174991607666,1.3539333269000053,7.222401681992614,16.06619653628267,-19.997907571436574,60.30071931454794,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-22,1.2100000381469727,1.3480000495910645,1.2000000476837158,1.3359999656677246,97732,0.0,0.0,1.281000006198883,1.0940749913454055,1.3492333268125851,4.2935175021617,17.085210459258573,-18.911357316526043,59.45654993218567,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-23,1.3320000171661377,1.3899999856948853,1.2300000190734863,1.2979999780654907,18877,0.0,0.0,1.3004000067710877,1.1033749908208847,1.3450499936938285,-0.18456080383729578,17.8565780074117,-17.967733839338305,56.747376863140644,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-24,1.2319999933242798,1.3940000534057617,1.2319999933242798,1.3600000143051147,46579,0.0,0.0,1.3270000100135804,1.114874991774559,1.341841660439968,2.4868126633395176,19.026798502438332,-16.91456416631083,59.95359968457792,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-25,1.3320000171661377,1.3539999723434448,1.2999999523162842,1.3459999561309814,96321,0.0,0.0,1.3266000032424927,1.125124990940094,1.3380999937653542,1.4623814896028275,17.90690047103629,-15.916224782720306,58.89200155414724,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-26,1.2799999713897705,1.2920000553131104,1.1959999799728394,1.2899999618530273,178498,0.0,0.0,1.3296000003814696,1.131374990940094,1.3329749936858812,-2.9783422470728658,17.520716917797902,-15.124064869989203,54.71830971435261,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-29,1.2899999618530273,1.305999994277954,1.2200000286102295,1.305999994277954,157957,0.0,0.0,1.3281999945640564,1.1401249915361404,1.3286499932408333,-1.6714350532269626,16.495998633844014,-14.18921481682652,55.68466247202358,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-04-30,1.3279999494552612,1.3459999561309814,1.2799999713897705,1.3300000429153442,17205,0.0,0.0,1.3215999960899354,1.1491249918937683,1.3248166605830192,0.6355967653042592,15.009246636601887,-13.261583577302941,57.16146889875028,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-02,1.3300000429153442,1.3919999599456787,1.2920000553131104,1.3179999589920044,17780,0.0,0.0,1.3183999896049499,1.1585249915719031,1.3202166602015495,-0.03034212804153119,13.799874771464882,-12.247358596805,56.15382814164507,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-03,1.3140000104904175,1.3600000143051147,1.2999999523162842,1.3600000143051147,44856,0.0,0.0,1.329199993610382,1.1708749920129775,1.3167166605591774,2.3171848362016263,13.521938949708959,-11.07616185886677,58.88561260738863,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-06,1.3600000143051147,1.3899999856948853,1.315999984741211,1.3899999856948853,83001,0.0,0.0,1.3333999872207642,1.1837749913334847,1.313133326669534,4.244787686858589,12.639648326979078,-9.851119662322288,60.76594078453543,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-07,1.3899999856948853,1.3899999856948853,1.3020000457763672,1.3559999465942383,116917,0.0,0.0,1.3353999853134155,1.1952749893069268,1.3088916594783464,1.5426060736392764,11.723243375797516,-8.680372385954472,57.553361993310915,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-08,1.3559999465942383,1.3880000114440918,1.149999976158142,1.3600000143051147,137081,0.0,0.0,1.341599988937378,1.206774990260601,1.3030583267410596,1.3714986225000358,11.172339480424736,-7.389027375410164,57.83579153640904,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-10,1.3600000143051147,1.399999976158142,1.222000002861023,1.399999976158142,61780,0.0,0.0,1.3455999851226808,1.219224989414215,1.2980999931693078,4.04280556160244,10.365190740486986,-6.076188596420804,60.655036966468174,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-13,1.399999976158142,1.399999976158142,1.1100000143051147,1.3459999561309814,179051,0.0,0.0,1.3455999851226808,1.2297249883413315,1.2911499922474226,0.029724361825422162,9.422838267086279,-4.757387156791324,55.281189448147096,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-14,1.2920000553131104,1.2920000553131104,1.1699999570846558,1.2139999866485596,213358,0.0,0.0,1.337999987602234,1.2357749879360198,1.2820999925335248,-9.267563684801585,8.272136971872962,-3.6132130775512556,44.826368141035395,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-15,1.2139999866485596,1.3339999914169312,1.2139999866485596,1.3339999914169312,98885,0.0,0.0,1.3407999873161316,1.2403749883174897,1.2755499934156735,-0.5071596034850758,8.096341827632598,-2.757634375740307,53.44599390179566,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-16,1.2000000476837158,1.3980000019073486,1.2000000476837158,1.3259999752044678,38661,0.0,0.0,1.340399980545044,1.2443999886512755,1.2695999935269355,-1.074306591284844,7.714560653268452,-1.984877520805166,52.8531747789723,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-17,1.3259999752044678,1.4040000438690186,1.2400000095367432,1.2400000095367432,54850,0.0,0.0,1.3325999855995179,1.2480249881744385,1.2624333277344704,-6.948820130829829,6.7767070552643585,-1.141314891130819,46.838623103692186,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-20,1.2400000095367432,1.3880000114440918,1.218000054359436,1.25,70397,0.0,0.0,1.3215999841690063,1.2498999893665315,1.255599994957447,-5.417674411824906,5.736458549680719,-0.45396667838539795,47.58553492019695,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-21,1.25,1.3899999856948853,1.1979999542236328,1.3899999856948853,88567,0.0,0.0,1.3215999841690063,1.2568999886512757,1.250099995235602,5.175544971641888,5.147585018849213,0.5439559588504879,56.74765286530335,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-22,1.2699999809265137,1.3179999589920044,1.2699999809265137,1.305999994277954,85068,0.0,0.0,1.3165999889373778,1.2614249885082245,1.2454833284020423,-0.8051036570324559,4.374021517871145,1.2799577274659568,50.98856810923848,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-23,1.2979999780654907,1.2979999780654907,1.2640000581741333,1.2860000133514404,12305,0.0,0.0,1.3091999888420105,1.264324989914894,1.2404499952991803,-1.7720726923539376,3.5493246819504156,1.9247043174808027,49.69539479226329,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-24,1.2719999551773071,1.2940000295639038,1.2619999647140503,1.2619999647140503,32398,0.0,0.0,1.2953999876976012,1.266624990105629,1.2373416617512702,-2.578355975046362,2.2717850837265225,2.3666323748375717,48.11828726996144,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-27,1.2619999647140503,1.3179999589920044,1.246000051498413,1.3140000104904175,33545,0.0,0.0,1.2921999931335448,1.2699749916791916,1.232958328227202,1.6870467011850294,1.7500345754814282,3.002263953657994,51.69522599250224,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-28,1.2999999523162842,1.2999999523162842,1.2120000123977661,1.2120000123977661,116903,0.0,0.0,1.2919999957084656,1.2741499930620193,1.2275583282113076,-6.191949193222066,1.4009341713018766,3.7954746247048816,45.12347823777143,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-29,1.2339999675750732,1.2860000133514404,1.2280000448226929,1.277999997138977,57193,0.0,0.0,1.2863999962806703,1.2803499937057494,1.2234999949733416,-0.6529850097932113,0.47252724682023517,4.646505841109259,49.58911244531783,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-30,1.2899999618530273,1.2899999618530273,1.2359999418258667,1.284000039100647,14126,0.0,0.0,1.282200002670288,1.285999995470047,1.2187833284338316,0.14038655643505304,-0.29548933228184165,5.51506288837988,49.987558709913394,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-05-31,1.2979999780654907,1.2979999780654907,1.2400000095367432,1.2879999876022339,33288,0.0,0.0,1.2870000004768372,1.288699996471405,1.2143083279331526,0.07769907731361542,-0.13191557377377147,6.126258613812921,50.2697546836076,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-03,1.2879999876022339,1.2979999780654907,1.2200000286102295,1.2519999742507935,46127,0.0,0.0,1.2871999979019164,1.2919999957084656,1.2093249941865603,-2.7346196168814143,-0.3715168593260786,6.836458513578957,47.66307446353439,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-04,1.2660000324249268,1.3480000495910645,1.2359999418258667,1.2599999904632568,29646,0.0,0.0,1.2741999983787538,1.2965999960899353,1.204491660495599,-1.1144253597209617,-1.72759507779821,7.647071259624775,48.30458808075441,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-05,1.25,1.3240000009536743,1.25,1.2999999523162842,59511,0.0,0.0,1.2735999941825866,1.3016499936580659,1.2001166597008706,2.0728610438351485,-2.154957139948928,8.460288684143634,51.505291397754625,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-07,1.2979999780654907,1.2999999523162842,1.2699999809265137,1.2999999523162842,92633,0.0,0.0,1.274999988079071,1.3065499931573867,1.1959916596611342,1.9607815271338473,-2.414756820906066,9.244072281204499,51.505291397754625,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-10,1.2999999523162842,1.440000057220459,1.2699999809265137,1.399999976158142,141358,0.0,0.0,1.2887999892234803,1.3141999930143355,1.1920749927560488,8.628180312265625,-1.932735042297189,10.244741396339228,58.88592774468221,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-11,1.4479999542236328,1.4479999542236328,1.350000023841858,1.4299999475479126,63982,0.0,0.0,1.3003999829292296,1.316199991106987,1.1888666585087777,9.966161667178062,-1.2004260966807054,10.71048058139055,60.81278386237354,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-12,1.437999963760376,1.5880000591278076,1.399999976158142,1.5219999551773071,215056,0.0,0.0,1.3313999772071838,1.3227499902248383,1.1867166583736737,14.31575643931856,0.6539396746376259,11.463000109696818,66.06516506763177,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-13,1.6480000019073486,1.7480000257492065,1.5,1.5839999914169312,276026,0.0,0.0,1.3619999766349793,1.3293499886989593,1.1884583249688148,16.299560836295715,2.4560866749601975,11.854994051545013,69.0735326756485,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-14,1.6480000019073486,1.6480000019073486,1.4620000123977661,1.5,102515,0.0,0.0,1.3835999727249146,1.3319499880075454,1.1896249915162722,8.412838216948119,3.8777720772108046,11.963853946096794,61.162351687596846,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-17,1.5,1.5,1.3359999656677246,1.440000057220459,92804,0.0,0.0,1.398799979686737,1.3341999888420104,1.1901666586597761,2.945387341437396,4.84185214997601,12.101946322746722,56.21012536756749,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-18,1.437999963760376,1.4700000286102295,1.437999963760376,1.465999960899353,48918,0.0,0.0,1.420199978351593,1.3395499885082245,1.1911333248019218,3.224896722003854,6.020677879530541,12.460121853360409,57.80449170885409,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-19,1.4579999446868896,1.6440000534057617,1.4140000343322754,1.4639999866485596,69991,0.0,0.0,1.4405999779701233,1.3424499869346618,1.19087499131759,1.6243238259248103,7.311258668159127,12.72803583265851,57.630669434347645,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-20,1.4199999570846558,1.503999948501587,1.3899999856948853,1.503999948501587,142388,0.0,0.0,1.4609999775886535,1.3466499865055084,1.1920749907692274,2.9431876504135097,8.491441148703965,12.966885215546393,60.20794059650339,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-24,1.4700000286102295,1.5759999752044678,1.4199999570846558,1.5199999809265137,78197,0.0,0.0,1.4829999804496765,1.352199986577034,1.1913249904910723,2.494942748793428,9.673124920208755,13.503871518690119,61.22399632559801,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-25,1.4600000381469727,1.5180000066757202,1.444000005722046,1.4500000476837158,42663,0.0,0.0,1.4879999876022338,1.354449987411499,1.1889499907692274,-2.553759424403706,9.860090917492153,13.919845067259423,54.64941534209917,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-26,1.472000002861023,1.5160000324249268,1.4199999570846558,1.4739999771118164,39970,0.0,0.0,1.4923999905586243,1.35764998793602,1.1870666568477948,-1.2329143368541902,9.925238744888823,14.37015605688075,56.378989352270814,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-27,1.4739999771118164,1.4739999771118164,1.4140000343322754,1.4600000381469727,48617,0.0,0.0,1.4861999988555907,1.3618999898433686,1.1844416573643683,-1.7628825682137441,9.126955719158044,14.982446064408297,55.05984564271014,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-06-28,1.4600000381469727,1.4700000286102295,1.399999976158142,1.4639999866485596,112537,0.0,0.0,1.4741999983787537,1.3658499896526337,1.182183323800564,-0.6919014883605727,7.932789804660454,15.536225402131848,55.38106886016385,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-01,1.4299999475479126,1.4579999446868896,1.399999976158142,1.4119999408721924,70667,0.0,0.0,1.4653999924659729,1.367899987101555,1.1802833234270413,-3.6440597699143527,7.127714473556714,15.8959005817141,50.34319645057363,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-02,1.4119999408721924,1.440000057220459,1.3519999980926514,1.399999976158142,156782,0.0,0.0,1.4613999843597412,1.3699499875307084,1.178908322751522,-4.201451269927257,6.675425939735836,16.204963616959056,49.23023864849265,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-03,1.3980000019073486,1.399999976158142,1.3700000047683716,1.3980000019073486,48363,0.0,0.0,1.4545999884605407,1.3708999872207641,1.1773499891161918,-3.8911031900319233,6.105478300387343,16.4394614935076,49.035667196895105,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-04,1.378000020980835,1.3899999856948853,1.3559999465942383,1.3799999952316284,39648,0.0,0.0,1.4461999893188477,1.3706499874591827,1.1756416554252307,-4.57751310857077,5.511983551666208,16.58739558385393,47.22655143683479,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-05,1.3799999952316284,1.3799999952316284,1.309999942779541,1.340000033378601,123213,0.0,0.0,1.429799997806549,1.3702499896287919,1.1753916556636492,-6.280596206861778,4.345922906658044,16.57816209824306,43.395073810270134,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-08,1.340000033378601,1.3519999980926514,1.2899999618530273,1.3519999980926514,61131,0.0,0.0,1.4129999995231628,1.3700499892234803,1.1758249893784523,-4.3170560121087584,3.1349228595684875,16.51818949244279,44.84085529505435,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-09,1.2599999904632568,1.350000023841858,1.2599999904632568,1.350000023841858,128811,0.0,0.0,1.402999997138977,1.3687999904155732,1.1780749892195066,-3.777617491460987,2.4985393748447193,16.18954675562928,44.63622730923299,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-10,1.350000023841858,1.350000023841858,1.2920000553131104,1.3320000171661377,77685,0.0,0.0,1.3888000011444093,1.3684499919414521,1.1804666563868522,-4.089860594143637,1.4870846083375042,15.924493465150077,42.745560070896204,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-11,1.3320000171661377,1.3320000171661377,1.2020000219345093,1.3300000429153442,13304,0.0,0.0,1.3758000016212464,1.3713499933481217,1.1825499897201857,-3.3289692289527077,0.32449836254128644,15.96549873317489,42.530004392866324,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-12,1.3020000457763672,1.4780000448226929,1.3020000457763672,1.3600000143051147,67126,0.0,0.0,1.365400004386902,1.3719999939203262,1.1852583234508833,-0.39548777387120937,-0.4810488019439162,15.755356176343394,46.85892767140235,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-15,1.350000023841858,1.3880000114440918,1.3079999685287476,1.312000036239624,37470,0.0,0.0,1.355400013923645,1.3716499954462051,1.188008323808511,-3.202005108321176,-1.1847032097480428,15.45794486093974,41.47575942614611,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-16,1.312000036239624,1.3380000591278076,1.25600004196167,1.2960000038146973,126109,0.0,0.0,1.3450000166893006,1.373049995303154,1.1900166576107343,-3.643123588594161,-2.042895649088173,15.380737447819135,39.83307569364338,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-17,1.1119999885559082,1.2899999618530273,1.1119999885559082,1.2680000066757202,28433,0.0,0.0,1.3320000171661377,1.373499995470047,1.1918749913573266,-4.804805530451798,-3.021476406318227,15.238595106847827,37.06637883334935,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-18,1.2740000486373901,1.3220000267028809,1.2580000162124634,1.2760000228881836,7936,0.0,0.0,1.3216000199317932,1.3706499963998795,1.193758325278759,-3.4503629203912243,-3.5785923902469574,14.81804711852493,38.38322268176197,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-19,1.2760000228881836,1.2999999523162842,1.2359999418258667,1.2979999780654907,16201,0.0,0.0,1.3174000144004823,1.370449995994568,1.1958249921600024,-1.4726002825967817,-3.8709899484939663,14.602889635141578,41.97868496822723,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-22,1.2979999780654907,1.2979999780654907,1.24399995803833,1.277999997138977,60429,0.0,0.0,1.3100000143051147,1.3702499955892562,1.197724992533525,-2.4427493753205765,-4.397006493565567,14.404392004110425,39.71012887139718,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-23,1.2979999780654907,1.4780000448226929,1.2979999780654907,1.3380000591278076,133921,0.0,0.0,1.3088000178337098,1.3721499979496001,1.200124993423621,2.2310544694543117,-4.616840739755422,14.333924005302151,48.67170384188417,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-24,1.350000023841858,1.434000015258789,1.3200000524520874,1.3860000371932983,88497,0.0,0.0,1.3142000198364259,1.3739499986171722,1.2030916606386504,5.463401025196239,-4.348773888488107,14.20160604286985,54.49861773171543,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-25,1.3799999952316284,1.4500000476837158,1.350000023841858,1.440000057220459,81593,0.0,0.0,1.3252000212669373,1.3796499997377396,1.2065916612744332,8.662845918442478,-3.946651576932762,14.342742786778235,60.000083356508306,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-26,1.2940000295639038,1.444000005722046,1.2940000295639038,1.440000057220459,48983,0.0,0.0,1.3332000255584717,1.3837000012397767,1.2108416616916657,8.01080330142127,-3.6496332757142174,14.275883050357773,60.000083356508306,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-29,1.440000057220459,1.4600000381469727,1.3200000524520874,1.4359999895095825,109365,0.0,0.0,1.3456000208854675,1.3875,1.215891661743323,6.7181901918095726,-3.019818314560899,14.113785270196525,59.383260242233575,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-30,1.399999976158142,1.4279999732971191,1.3519999980926514,1.4279999732971191,68697,0.0,0.0,1.3588000178337096,1.390999999642372,1.2210416615009307,5.092725533940802,-2.314880073108635,13.919126881594268,58.0968787178219,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-07-31,1.4459999799728394,1.4459999799728394,1.3660000562667847,1.3940000534057617,11915,0.0,0.0,1.3714000225067138,1.3945500016212464,1.2258249953389169,1.6479532250363007,-1.6600322030489718,13.764200185498776,52.85635515007657,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-01,1.4479999542236328,1.4500000476837158,1.3660000562667847,1.4179999828338623,8149,0.0,0.0,1.3856000185012818,1.3985000014305116,1.2300083284576735,2.338334577075538,-0.9224156536313564,13.69841724438666,55.88158602342075,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-02,1.4179999828338623,1.4179999828338623,1.2860000133514404,1.2899999618530273,130850,0.0,0.0,1.3848000168800354,1.39825000166893,1.2333083281914392,-6.845757789676611,-0.9619155925507599,13.373920349614957,40.8320955606347,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-05,1.2899999618530273,1.2899999618530273,1.1019999980926514,1.2000000476837158,318940,0.0,0.0,1.3770000219345093,1.395750004053116,1.2358416616916656,-12.85402842638529,-1.3433624978798873,12.9392257372649,33.91582206874379,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-06,1.25,1.2920000553131104,1.159999966621399,1.2480000257492065,111993,0.0,0.0,1.3680000185966492,1.3919500052928924,1.2387416621049245,-8.771929182467673,-1.7206068181452845,12.36806251657262,39.774929157385905,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-07,1.246000051498413,1.2999999523162842,1.1419999599456787,1.2999999523162842,35863,0.0,0.0,1.3594000101089478,1.3887000054121017,1.242158328493436,-4.369579031259761,-2.1098865981828077,11.797342863401328,45.42052368049051,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-08,1.2280000448226929,1.2999999523162842,1.2259999513626099,1.2699999809265137,68214,0.0,0.0,1.3424000024795533,1.382400006055832,1.2450249950091044,-5.393326982964033,-2.8935187645436926,11.033915913127752,42.920740382237796,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-09,1.2979999780654907,1.2979999780654907,1.2079999446868896,1.2480000257492065,25577,0.0,0.0,1.323199999332428,1.3740000069141387,1.247758328417937,-5.683190267620978,-3.697234885449696,10.11747833062085,41.13291400157084,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-12,1.2480000257492065,1.25600004196167,1.215999960899353,1.2480000257492065,90598,0.0,0.0,1.3044000029563905,1.367700007557869,1.2506583288311959,-4.323825289738942,-4.6282082512016185,9.35840557157241,41.13291400157084,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-13,1.222000002861023,1.253999948501587,1.1679999828338623,1.194000005722046,36698,0.0,0.0,1.281000006198883,1.3615500062704087,1.2528916622201602,-6.791569091009817,-5.916051536892876,8.672604928801482,36.77254434834794,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-14,1.2079999446868896,1.2339999675750732,1.2000000476837158,1.2339999675750732,91709,0.0,0.0,1.2649999976158142,1.3557500064373016,1.2559249952435494,-2.450595264756337,-6.693712586435033,7.948325861162919,41.70240673438698,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-15,1.2359999418258667,1.4019999504089355,1.1720000505447388,1.2899999618530273,197342,0.0,0.0,1.2521999955177308,1.3514000058174134,1.2590083281199138,3.018684433046011,-7.340536471263376,7.338448494258073,47.83471229277333,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-16,1.350000023841858,1.350000023841858,1.24399995803833,1.2719999551773071,126057,0.0,0.0,1.2503999948501587,1.3456000059843063,1.2621083279450735,1.7274440511923401,-7.074911616436026,6.615254506336342,46.15415496633454,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-19,1.2899999618530273,1.4700000286102295,1.2719999551773071,1.3600000143051147,172019,0.0,0.0,1.2663999915122985,1.3416000068187715,1.2657249947388967,7.391031539809294,-5.605248578135347,5.994589061230229,54.559380808340734,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-20,1.3580000400543213,1.3580000400543213,1.2920000553131104,1.3240000009536743,26692,0.0,0.0,1.2739999890327454,1.3384500056505204,1.2692583282788594,3.924647751283757,-4.815272617257805,5.451347123755834,51.04873847453462,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-21,1.2799999713897705,1.3819999694824219,1.2719999551773071,1.378000020980835,57100,0.0,0.0,1.2817999958992004,1.3360500067472458,1.2729416618744531,7.505072974676441,-4.060477570006742,4.957677697488773,55.657779101022406,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-22,1.3600000143051147,1.4579999446868896,1.2660000324249268,1.3519999980926514,94861,0.0,0.0,1.2899999976158143,1.3333500057458878,1.2755416621764502,4.806201596234561,-3.2512099556202516,4.532062360926696,53.066969899577195,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-23,1.3539999723434448,1.4040000438690186,1.3539999723434448,1.3880000114440918,25801,0.0,0.0,1.3039999961853028,1.3314500063657762,1.2791416625181833,6.441718980408055,-2.0616628524715526,4.089331571345741,56.11316316029194,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-26,1.3559999465942383,1.3899999856948853,1.3300000429153442,1.3899999856948853,69169,0.0,0.0,1.3181999921798706,1.3309000074863433,1.2826416621605554,5.446820963508048,-0.9542426354372838,3.7624183549830077,56.28292356253517,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-27,1.3700000047683716,1.3940000534057617,1.3420000076293945,1.3940000534057617,28855,0.0,0.0,1.338199996948242,1.330750009417534,1.2864083295067152,4.169784530322175,0.5598337387176857,3.4469366291978174,56.64414827984556,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-28,1.399999976158142,1.399999976158142,1.3200000524520874,1.340000033378601,56456,0.0,0.0,1.348800003528595,1.329300010204315,1.2903583298126857,-0.6524295764362618,1.4669369724357935,3.0178966177001643,50.56943590951727,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-29,1.340000033378601,1.4040000438690186,1.3200000524520874,1.3200000524520874,8488,0.0,0.0,1.351800012588501,1.3278000116348267,1.2940749968091647,-2.352416026060046,1.8075011856736438,2.606109762480436,48.495055175412276,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-08-30,1.3639999628067017,1.3639999628067017,1.2200000286102295,1.3539999723434448,96397,0.0,0.0,1.3600000143051147,1.3281500101089478,1.2978916630148887,-0.4411795513646089,2.398072804558745,2.331346132832973,52.09282919049209,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-02,1.2699999809265137,1.3140000104904175,1.2699999809265137,1.3140000104904175,50087,0.0,0.0,1.355400013923645,1.327200010418892,1.301341663300991,-3.054449093104392,2.1247742076081395,1.9870528891166341,47.85737315407279,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-03,1.4320000410079956,1.4559999704360962,1.2860000133514404,1.312000036239624,12729,0.0,0.0,1.35420001745224,1.326250010728836,1.304758330186208,-3.1162295575811596,2.107446295743602,1.6471771090023068,47.64876877216603,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-04,1.2519999742507935,1.309999942779541,1.2519999742507935,1.309999942779541,24455,0.0,0.0,1.3474000096321106,1.325700008869171,1.3079583297173183,-2.7757211359068616,1.636871133571897,1.3564407021810223,47.42612896518089,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-05,1.3140000104904175,1.3240000009536743,1.2519999742507935,1.2979999780654907,122069,0.0,0.0,1.3420000076293945,1.324900007247925,1.3106749961773554,-3.2786907089239614,1.2906634680295357,1.085319481340333,46.03628586778871,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-06,1.2960000038146973,1.3480000495910645,1.277999997138977,1.3179999589920044,124088,0.0,0.0,1.3350000023841857,1.323850005865097,1.3120749960343043,-1.2734114877768399,0.8422401684247047,0.89743420661031,48.73291379073322,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-09,1.3179999589920044,1.3179999589920044,1.2139999866485596,1.2960000038146973,177839,0.0,0.0,1.325600004196167,1.323450005054474,1.3131666630506516,-2.2329511381843283,0.16245412622176233,0.7830949637369652,46.009322538135336,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-10,1.246000051498413,1.2719999551773071,1.222000002861023,1.2400000095367432,139830,0.0,0.0,1.310199999809265,1.322050005197525,1.314374996225039,-5.357959875037505,-0.8963356409873082,0.5839284066213244,39.89694631126344,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-11,1.2380000352859497,1.2400000095367432,1.2380000352859497,1.2400000095367432,7238,0.0,0.0,1.3001999974250793,1.3213500052690506,1.314916663368543,-4.630055991967113,-1.6006363007252369,0.48925852715461915,39.89694631126344,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-12,1.2400000095367432,1.2400000095367432,1.2000000476837158,1.2400000095367432,114722,0.0,0.0,1.2921999931335448,1.3204500049352645,1.3159999966621398,-4.039621101546234,-2.1394230524543545,0.33814652617109064,39.89694631126344,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-13,1.2380000352859497,1.25600004196167,1.2100000381469727,1.2300000190734863,67743,0.0,0.0,1.279799997806549,1.3187500059604644,1.3168749968210856,-3.8912313500871223,-2.9535551073266166,0.14238322877305146,38.748823325790404,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-16,1.2300000190734863,1.305999994277954,1.1740000247955322,1.194000005722046,46782,0.0,0.0,1.2677999973297118,1.3166500061750412,1.317074997226397,-5.821106780494262,-3.7101742009056795,-0.03226779433599683,34.859631964949955,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-17,1.1979999542236328,1.1979999542236328,1.1740000247955322,1.1959999799728394,52082,0.0,0.0,1.2561999917030335,1.313100004196167,1.3172916640837988,-4.792231501974528,-4.333258115246563,-0.3182028704741941,35.24845977785208,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-18,1.187999963760376,1.2000000476837158,1.187999963760376,1.2000000476837158,50115,0.0,0.0,1.2452000021934508,1.3084500044584275,1.3174583315849304,-3.6299353059841124,-4.833964006989789,-0.6837656197950255,36.070393441798885,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-19,1.1979999542236328,1.2100000381469727,1.1019999980926514,1.1679999828338623,388396,0.0,0.0,1.2322000026702882,1.3016500025987625,1.318483331799507,-5.2101947490097915,-5.335535650122263,-1.276719151069577,32.51462395023654,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-20,1.1679999828338623,1.1699999570846558,1.1540000438690186,1.1699999570846558,74798,0.0,0.0,1.2174000024795533,1.2949000000953674,1.3196499983469645,-3.893547338455308,-5.985017963557526,-1.8754971608077677,32.9594381008736,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-23,1.1419999599456787,1.3480000495910645,1.1419999599456787,1.2999999523162842,59256,0.0,0.0,1.217799997329712,1.291499999165535,1.3216666648785274,6.749873145575072,-5.706542925547196,-2.282471557665034,54.12562739279876,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-24,1.2999999523162842,1.2999999523162842,1.2879999876022339,1.2879999876022339,5791,0.0,0.0,1.222599995136261,1.2879999995231628,1.3225666652123134,5.349255089657022,-5.077640094030585,-2.613604788201851,52.47857144978829,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-25,1.25,1.3079999685287476,1.218000054359436,1.24399995803833,27599,0.0,0.0,1.2229999899864197,1.2842499971389771,1.3235999981562296,1.717086526888981,-4.769321182714334,-2.9729526346378754,46.84913794480635,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-26,1.2799999713897705,1.378000020980835,1.2020000219345093,1.3320000171661377,137711,0.0,0.0,1.232199990749359,1.282099997997284,1.3257333318392435,8.099336728292421,-3.892052673416406,-3.291260225118211,56.824613379986346,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-27,1.3320000171661377,1.378000020980835,1.2580000162124634,1.2879999876022339,11377,0.0,0.0,1.2379999876022338,1.282049998641014,1.3273166646560033,4.038772253692858,-3.43590430057125,-3.410389338155474,51.60902146805025,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-09-30,1.2660000324249268,1.3279999494552612,1.1619999408721924,1.3279999494552612,45114,0.0,0.0,1.2513999819755555,1.2852499961853028,1.3291833311319352,6.121141807815852,-2.6337299599467916,-3.3052878348405645,55.59883645130877,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-01,1.350000023841858,1.350000023841858,1.340000033378601,1.340000033378601,10373,0.0,0.0,1.2657999873161316,1.2875499963760375,1.3312333315610885,5.861909212038733,-1.6892554946311877,-3.281418377184495,56.75089581631798,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-02,1.2999999523162842,1.4279999732971191,1.2999999523162842,1.3880000114440918,247922,0.0,0.0,1.284599983692169,1.2897499978542328,1.3315499981244405,8.04920045652909,-0.39930328905848816,-3.1391987029465835,61.09884484528053,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-03,1.4199999570846558,1.440000057220459,1.350000023841858,1.399999976158142,91715,0.0,0.0,1.3077999830245972,1.2929999977350235,1.332716664671898,7.050007212900443,1.1446237676333468,-2.9801283340785973,62.12401252443265,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-04,1.399999976158142,1.399999976158142,1.3380000591278076,1.3899999856948853,67090,0.0,0.0,1.3297999858856202,1.2965499967336656,1.3332999974489212,4.526996574539219,2.564497260863037,-2.756318966892039,60.6887062369506,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-07,1.350000023841858,1.3880000114440918,1.343999981880188,1.3880000114440918,44851,0.0,0.0,1.3385999917984008,1.3000499963760377,1.3332333306471507,3.6904243200631086,2.9652702226701604,-2.4889367456036973,60.38820469210339,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-08,1.3320000171661377,1.3839999437332153,1.3320000171661377,1.3799999952316284,62536,0.0,0.0,1.3477999925613404,1.304699996113777,1.3334833304087321,2.3890787096010855,3.3034411417139906,-2.1585072447911697,59.12702774437597,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-09,1.3819999694824219,1.3839999437332153,1.3819999694824219,1.3819999694824219,20313,0.0,0.0,1.3615999937057495,1.308399996161461,1.334566663702329,1.4982355956944118,4.0660346759679635,-1.9606864349718571,59.35555778345347,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-10,1.378000020980835,1.440000057220459,1.350000023841858,1.4299999475479126,32442,0.0,0.0,1.371399986743927,1.311899995803833,1.3352499961853028,4.273002870819449,4.535405986005577,-1.7487362252895502,64.48758136357938,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-11,1.4299999475479126,1.4299999475479126,1.3680000305175781,1.4299999475479126,29804,0.0,0.0,1.3855999827384948,1.3158499956130982,1.3360333293676376,3.2043854909456506,5.300755204463694,-1.5106908870374096,64.48758136357938,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-14,1.4199999570846558,1.4199999570846558,1.3339999914169312,1.4040000438690186,38430,0.0,0.0,1.3931999921798706,1.3169499963521958,1.3369166632493337,0.7751975129033478,5.789893013317038,-1.4934862767443957,59.74829391076839,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-15,1.3819999694824219,1.437999963760376,1.3819999694824219,1.399999976158142,33500,0.0,0.0,1.3991999864578246,1.3188499957323074,1.3372499962647757,0.05717479331476432,6.092428326612071,-1.3759581666751457,59.02952949060706,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-16,1.3799999952316284,1.5,1.3619999885559082,1.5,125175,0.0,0.0,1.4103999853134155,1.3218999952077866,1.3385333299636841,6.352808821582186,6.694908119106076,-1.2426537601681422,69.05263292924361,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-17,1.5700000524520874,1.746000051498413,1.5019999742507935,1.5859999656677246,474512,0.0,0.0,1.4289999842643737,1.3277499943971633,1.34099999666214,10.986702808409895,7.625681814683852,-0.9880687768797157,74.76930555811558,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-18,1.5859999656677246,1.809999942779541,1.5679999589920044,1.7799999713897705,312724,0.0,0.0,1.4679999828338623,1.3375499933958053,1.3449499964714051,21.25340546350797,9.752905691911177,-0.5502065574939149,82.58454874744268,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-21,1.784000039100647,1.809999942779541,1.7020000219345093,1.7599999904632568,62147,0.0,0.0,1.5051999807357788,1.3467999935150146,1.3485333293676376,16.92798385520345,11.761210868984037,-0.1285348915651819,79.83892822143446,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-22,1.7599999904632568,1.7979999780654907,1.600000023841858,1.7899999618530273,55445,0.0,0.0,1.5461999773979187,1.3566999912261963,1.3524666627248128,15.767687751838977,13.967714852010191,0.313007974100796,80.8664997929049,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-23,1.7899999618530273,1.9980000257492065,1.7580000162124634,1.9299999475479126,142772,0.0,0.0,1.6009999752044677,1.371449989080429,1.357216662168503,20.54965505551788,16.73775842733822,1.048714424798229,84.76811153724364,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-24,1.9900000095367432,2.140000104904175,1.9299999475479126,2.0950000286102295,328344,0.0,0.0,1.6674999833106994,1.3908249884843826,1.3630916625261307,25.63718438250056,19.89286913286024,2.0345899487680494,87.89982560842617,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-25,2.059999942779541,2.134999990463257,1.9420000314712524,2.075000047683716,87443,0.0,0.0,1.7319999933242798,1.4088499903678895,1.3690833300352097,19.803698364981265,22.93714768539743,2.904619423834277,85.60238483636451,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-28,2.075000047683716,2.075000047683716,1.8339999914169312,2.0250000953674316,41553,0.0,0.0,1.794099998474121,1.4266249924898147,1.3746249973773956,12.869968066980142,25.758346301151736,3.782849519805635,79.97465333697562,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-29,2.0299999713897705,2.25,2.0299999713897705,2.0999999046325684,196150,0.0,0.0,1.8640999913215637,1.4463249891996384,1.3804583301146824,12.654895896639223,28.88527856751697,4.771361630269855,81.8971664681969,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-30,1.940000057220459,1.940000057220459,1.5,1.7339999675750732,672520,0.0,0.0,1.887499988079071,1.4569249898195267,1.3836916635433834,-8.132451468792667,29.55368335832313,5.292604429559549,54.43339279614283,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-10-31,1.7300000190734863,2.0999999046325684,1.715999960899353,1.8580000400543213,96659,0.0,0.0,1.9146999955177306,1.4709249913692475,1.3890583306550979,-2.961297101172123,30.169791576889587,5.893680553756172,59.40084749277294,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-01,1.8580000400543213,1.940000057220459,1.7719999551773071,1.9119999408721924,170182,0.0,0.0,1.927899992465973,1.485774990916252,1.3938749969005584,-0.824734252602122,29.75719770845449,6.5931302462590935,61.375565395868804,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-04,2.069999933242798,2.069999933242798,1.8799999952316284,1.9299999475479126,54315,0.0,0.0,1.9448999881744384,1.5016249895095826,1.3989083300034204,-0.7661083200741655,29.51968712305631,7.3426297708807695,62.0383877275408,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-05,1.812000036239624,1.9539999961853027,1.812000036239624,1.9160000085830688,15478,0.0,0.0,1.9574999928474426,1.5185249894857407,1.4045416633288066,-2.12005028945142,28.907986789889044,8.115339625226218,61.159293124714,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-06,2.055000066757202,2.059999942779541,1.555999994277954,2.009999990463257,33558,0.0,0.0,1.965499997138977,1.5377749890089034,1.410874996582667,2.26405461150114,27.814537964734527,8.99441784237481,64.76910898625403,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-07,2.0399999618530273,2.0399999618530273,1.7960000038146973,1.899999976158142,52035,0.0,0.0,1.9459999918937683,1.5542749881744384,1.4151249965031942,-2.3638240455931774,25.203069386031064,9.833053052916666,57.97841839576248,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-08,1.7020000219345093,1.9279999732971191,1.7020000219345093,1.8839999437332153,107623,0.0,0.0,1.9268999814987182,1.5706249862909316,1.4199416627486547,-2.2263759498370947,22.68364493863927,10.611937623591617,57.041610370451515,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-11,1.8459999561309814,1.940000057220459,1.7200000286102295,1.815999984741211,200136,0.0,0.0,1.9059999704360961,1.586174985766411,1.4243583291769029,-4.7219300677267615,20.163285106602004,11.360670505084027,53.113685708886656,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-12,1.8980000019073486,1.8980000019073486,1.6200000047683716,1.718000054359436,83651,0.0,0.0,1.867799985408783,1.5992249876260758,1.4281583299239478,-8.02012700608101,16.79407211998268,11.97812974358646,47.985292486111064,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-13,1.690000057220459,1.7979999780654907,1.5440000295639038,1.6180000305175781,84499,0.0,0.0,1.8561999917030334,1.6096749871969223,1.430691663424174,-12.832666859722949,15.31520378131788,12.510265373628796,43.382240540149176,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-14,1.6160000562667847,1.7799999713897705,1.3600000143051147,1.7799999713897705,133887,0.0,0.0,1.8483999848365784,1.62497498691082,1.435424996415774,-3.7004984856053933,13.749442282216497,13.205147671828799,51.499082976677336,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-15,1.7799999713897705,1.7799999713897705,1.5180000066757202,1.6160000562667847,22932,0.0,0.0,1.8187999963760375,1.6361249893903733,1.4382416635751725,-11.15020565830944,11.165100965405438,13.75869791751851,44.53797522161559,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-18,1.5199999809265137,1.5499999523162842,1.399999976158142,1.4759999513626099,214221,0.0,0.0,1.7733999967575074,1.6405249893665315,1.439841662844022,-16.770048829292044,8.099541808399028,13.937874677560947,39.61519870154322,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-19,1.4040000438690186,1.6480000019073486,1.4040000438690186,1.4880000352859497,65135,0.0,0.0,1.7305999994277954,1.6455249905586242,1.441508329908053,-14.018257495785209,5.170083065118923,14.152999078651481,40.22507158158022,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-20,1.4859999418258667,1.6239999532699585,1.4279999732971191,1.5099999904632568,58478,0.0,0.0,1.6805999994277954,1.6521749913692474,1.443658330043157,-10.151137035738653,1.7204598911759719,14.443629561563714,41.39370458179244,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-21,1.440000057220459,1.593999981880188,1.4299999475479126,1.5219999551773071,41537,0.0,0.0,1.6427999973297118,1.6569249898195266,1.4458416630824407,-7.353301823031351,-0.8524823137197844,14.599339065044648,42.05911116116164,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-22,1.534000039100647,1.6460000276565552,1.5,1.5640000104904175,37986,0.0,0.0,1.6108000040054322,1.6638249903917313,1.448041663567225,-2.9053882169506693,-3.1869329221828093,14.901734684410101,44.43695555722446,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-25,1.5199999809265137,1.590000033378601,1.5099999904632568,1.5779999494552612,65966,0.0,0.0,1.5870000004768372,1.6700749903917314,1.45035833021005,-0.5671109652723236,-4.974326925008808,15.149129398240543,45.24362193353482,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-26,1.5420000553131104,1.777999997138977,1.5420000553131104,1.7419999837875366,27491,0.0,0.0,1.5893999934196472,1.6801249891519547,1.4532083302736283,9.60110676982988,-5.3998956219382865,15.614874629544667,53.71989165976324,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-27,1.6080000400543213,1.8200000524520874,1.6080000400543213,1.75,27948,0.0,0.0,1.6025999903678894,1.6891749888658523,1.4558749973773957,9.19755463110129,-5.1252829972394505,16.024726841845744,54.093209374126594,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-28,1.75,1.909999966621399,1.7000000476837158,1.840000033378601,127862,0.0,0.0,1.6085999965667725,1.7001749902963639,1.458524998029073,14.385181978472245,-5.386209904995046,16.568107683710327,58.18019166657777,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-11-29,1.75,1.899999976158142,1.75,1.8179999589920044,9588,0.0,0.0,1.6287999868392944,1.7108749896287918,1.4604749977588654,11.615911940167361,-4.7972530598103615,17.14510636978869,56.84787871497947,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-02,1.600000023841858,1.7480000257492065,1.4520000219345093,1.7100000381469727,40391,0.0,0.0,1.6521999955177307,1.718924990296364,1.4622249980767568,3.498368404917582,-3.881786299885549,17.555437265621972,50.70886046361968,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-03,1.6920000314712524,1.8140000104904175,1.6519999504089355,1.7400000095367432,63729,0.0,0.0,1.67739999294281,1.7279249906539917,1.4647249976793926,3.731967143037148,-2.924027257228266,17.969242922159093,52.2513693303305,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-04,1.7400000095367432,1.7400000095367432,1.621999979019165,1.6779999732971191,9664,0.0,0.0,1.6941999912261962,1.735324990749359,1.466491664449374,-0.9562045810986081,-2.3698730636849747,18.33173231168173,48.84908188628039,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-05,1.6360000371932983,1.6740000247955322,1.6200000047683716,1.659999966621399,10695,0.0,0.0,1.7079999923706055,1.7410749912261962,1.4681249976158142,-2.81030596976674,-1.8996883547386334,18.591740761423157,47.87444578986457,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-06,1.6579999923706055,1.659999966621399,1.5959999561309814,1.6299999952316284,43606,0.0,0.0,1.7145999908447265,1.7460749924182892,1.4691749980052313,-4.934095186330803,-1.8026145331805206,18.847311912401054,46.21927772515932,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-09,1.5,1.656000018119812,1.4500000476837158,1.6260000467300415,40986,0.0,0.0,1.7194000005722045,1.7516249924898148,1.4700583318869274,-5.432124799993031,-1.8397198062243154,19.153434560754885,45.990965530455014,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-10,1.562000036239624,1.6740000247955322,1.562000036239624,1.6740000247955322,45315,0.0,0.0,1.712600004673004,1.7584749937057496,1.471924998362859,-2.2538818038157125,-2.6087939377556957,19.46770356245082,49.23188552952399,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-11,1.6059999465942383,1.6699999570846558,1.5420000553131104,1.5740000009536743,117086,0.0,0.0,1.6950000047683715,1.7603249937295913,1.4727583318948745,-7.13864327282007,-3.710961850448765,19.52571957034722,43.39021039602482,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-12,1.5820000171661377,1.621999979019165,1.534000039100647,1.621999979019165,35593,0.0,0.0,1.673199999332428,1.7612249940633773,1.4741083314021428,-3.0600059965151045,-4.997941491158608,19.47731089669202,46.66177222679842,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-13,1.5800000429153442,1.590000033378601,1.534000039100647,1.565999984741211,13154,0.0,0.0,1.6480000019073486,1.7558749943971634,1.4749583313862482,-4.975729191215606,-6.143660159979158,19.045735532534948,43.503026341648074,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-16,1.5360000133514404,1.5820000171661377,1.5099999904632568,1.5520000457763672,74100,0.0,0.0,1.632200002670288,1.7506749957799912,1.4761249989271163,-4.9136108787350405,-6.767389343840949,18.5993731596189,42.72435917908206,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-17,1.5800000429153442,1.5980000495910645,1.503999948501587,1.5959999561309814,49945,0.0,0.0,1.617799997329712,1.74582499563694,1.4777583320935568,-1.3475115116029737,-7.33320914909458,18.14008811329862,45.99602154363625,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-18,1.649999976158142,1.649999976158142,1.5,1.600000023841858,28883,0.0,0.0,1.6100000023841858,1.7375749975442887,1.4794416656096776,-0.6211166787279099,-7.342128848562182,17.44802366561945,46.2963541781874,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-19,1.6299999952316284,1.6299999952316284,1.5099999904632568,1.628000020980835,161111,0.0,0.0,1.6068000078201294,1.7258999973535538,1.481508332490921,1.3193933941702298,-6.900746840260092,16.49613839509947,48.4571824486812,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-20,1.649999976158142,1.6720000505447388,1.5399999618530273,1.6200000047683716,41459,0.0,0.0,1.6058000087738038,1.7145249962806701,1.4838416655858357,0.8842941784145938,-6.341405797099729,15.546357542383623,47.86460040924954,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-23,1.6059999465942383,1.75600004196167,1.4739999771118164,1.6759999990463257,48281,0.0,0.0,1.6108000040054322,1.7057999938726425,1.486541665593783,4.047677854405666,-5.569233802817278,14.749558209744427,52.26515712014257,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-27,1.6019999980926514,1.7239999771118164,1.6019999980926514,1.6920000314712524,25535,0.0,0.0,1.6126000046730042,1.6955999970436095,1.4893916656573614,4.923727307959954,-4.895021969528265,13.845137994325729,53.47350725537813,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2024-12-30,1.6779999732971191,1.7000000476837158,1.4759999513626099,1.5820000171661377,52100,0.0,0.0,1.6134000062942504,1.6917999982833862,1.4914749989906946,-1.9461998887823235,-4.634117039170453,13.431334714175888,45.033389665068334,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-02,1.5759999752044678,1.5759999752044678,1.4359999895095825,1.5099999904632568,110355,0.0,0.0,1.6022000074386598,1.6830999970436096,1.492974998553594,-5.754588475055465,-4.806606247225469,12.734640477851947,40.52466364333713,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-03,1.6399999856948853,1.6399999856948853,1.4800000190734863,1.5160000324249268,42841,0.0,0.0,1.5972000122070313,1.673199999332428,1.4942749987045925,-5.083895514745295,-4.542193829531383,11.97403428304349,41.05429983282839,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-07,1.5219999551773071,1.9579999446868896,1.5219999551773071,1.6019999980926514,125450,0.0,0.0,1.6022000074386598,1.6650000005960464,1.4966916650533677,-0.012483419365858851,-3.7717713594537594,11.245357976699715,48.17768213462431,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-08,1.6119999885559082,1.7200000286102295,1.5,1.6299999952316284,108459,0.0,0.0,1.6056000113487243,1.6578500002622605,1.4994749983151754,1.5196801015470722,-3.151671677490157,10.5620301855674,50.28423629688313,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-09,1.6299999952316284,1.6299999952316284,1.5440000295639038,1.5980000495910645,14160,0.0,0.0,1.605400013923645,1.6475500017404556,1.5022249986728033,-0.46094208723063856,-2.558343465890791,9.673983803760759,47.88837415184466,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-10,1.565999984741211,1.6080000400543213,1.5,1.5859999656677246,13726,0.0,0.0,1.601200008392334,1.6397000014781953,1.5048083315292995,-0.9492906972858881,-2.3479900622768497,8.964043268673873,46.98430326484892,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-13,1.5199999809265137,1.6080000400543213,1.4579999446868896,1.534000039100647,75466,0.0,0.0,1.5926000118255614,1.630950003862381,1.5067749987045924,-3.6795160297495313,-2.351389800177805,8.241111331455894,43.18013661395255,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-14,1.409999966621399,1.6080000400543213,1.409999966621399,1.5399999618530273,77050,0.0,0.0,1.5790000081062316,1.6240500032901763,1.5089583317438762,-2.469920586002965,-2.7739290719299,7.6272266188616875,43.74609826545843,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-15,1.4900000095367432,1.5499999523162842,1.399999976158142,1.5160000324249268,247204,0.0,0.0,1.561400008201599,1.6190000027418137,1.5104416648546855,-2.90764541681817,-3.557751355322277,7.18719169452812,41.946277593272086,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-16,1.5199999809265137,1.6100000143051147,1.4119999408721924,1.6100000143051147,118896,0.0,0.0,1.5642000079154967,1.6188000023365021,1.5123083313306174,2.928014714093537,-3.3728684421916384,7.041663978151012,50.53098778710228,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-17,1.6119999885559082,1.6979999542236328,1.5299999713897705,1.6699999570846558,161467,0.0,0.0,1.5802000045776368,1.6160500019788742,1.514224997162819,5.68282193689913,-2.218371792787266,6.72456240035947,55.095488627636584,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-20,1.6699999570846558,1.8200000524520874,1.6139999628067017,1.7139999866485596,28646,0.0,0.0,1.6,1.6185000002384187,1.516508329908053,7.124999165534968,-1.1430336877166125,6.7254276365596635,58.14541862089152,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-21,1.6380000114440918,1.809999942779541,1.6380000114440918,1.7400000095367432,46648,0.0,0.0,1.6138000011444091,1.625100001692772,1.5190416634082795,7.820052565549673,-0.6953418581374823,6.981924251276222,59.879508432919884,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-22,1.6200000047683716,1.6959999799728394,1.6139999628067017,1.6920000314712524,84583,0.0,0.0,1.6200000047683716,1.6302000015974045,1.521241663893064,4.444446079688466,-0.6256899042472177,7.162460790450704,55.32247536314869,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-23,1.7799999713897705,1.7799999713897705,1.6200000047683716,1.6979999542236328,57429,0.0,0.0,1.6299999952316284,1.6349000006914138,1.5237749963998795,4.171776637480381,-0.29971285446896817,7.29274365008495,55.77553548786006,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-24,1.7000000476837158,1.7000000476837158,1.6519999504089355,1.6979999542236328,33557,0.0,0.0,1.6411999940872193,1.639300000667572,1.5261083294947941,3.460879864796964,0.11590272792494183,7.417014178164472,55.775535487860054,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-27,1.6979999542236328,1.6979999542236328,1.649999976158142,1.6959999799728394,6375,0.0,0.0,1.6573999881744386,1.6425999999046326,1.529491662979126,2.3289484779662137,0.9010098788911035,7.395158774856967,55.55773473375968,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-28,1.6200000047683716,1.7000000476837158,1.5119999647140503,1.5740000009536743,206873,0.0,0.0,1.6607999920845031,1.642500001192093,1.5326083292563757,-5.226396408027701,1.1141546958373474,7.170238464581286,44.21525941182536,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-29,1.5720000267028809,1.590000033378601,1.531999945640564,1.590000033378601,12491,0.0,0.0,1.6681999921798707,1.6387000024318694,1.535458329319954,-4.687684879981576,1.8002068532509061,6.723834254599447,45.7786917662978,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-30,1.687999963760376,1.687999963760376,1.4700000286102295,1.5499999523162842,36976,0.0,0.0,1.6621999859809875,1.6337000012397767,1.5375416626532872,-6.750092324088534,1.7445053999867097,6.2540314140530056,42.56681051979919,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-01-31,1.5199999809265137,1.6039999723434448,1.5099999904632568,1.5640000104904175,28040,0.0,0.0,1.6515999913215638,1.626800000667572,1.539991662899653,-5.30394655433797,1.5244646326416798,5.636935566551535,44.046521329501836,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-03,1.562000036239624,1.6540000438690186,1.4500000476837158,1.6059999465942383,220261,0.0,0.0,1.6407999873161316,1.6215000003576279,1.5429749955733618,-2.120919124263039,1.1902551313134186,5.089194900082393,48.34605066526708,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-04,1.5499999523162842,1.5980000495910645,1.50600004196167,1.5980000495910645,31771,0.0,0.0,1.6265999913215636,1.6187000006437302,1.5458916624387105,-1.7582652086000925,0.48804538671104764,4.709795645715656,47.59583993944541,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-05,1.5140000581741333,1.5460000038146973,1.496000051498413,1.5460000038146973,31080,0.0,0.0,1.6119999885559082,1.613850000500679,1.5488249957561493,-4.094291886461877,-0.11463345070464491,4.198344223698689,42.93235099832388,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-06,1.5199999809265137,1.690000057220459,1.5199999809265137,1.690000057220459,31979,0.0,0.0,1.6111999988555907,1.6141500025987625,1.5526249965031942,4.890768273388695,-0.18275895910679363,3.962644311030307,55.83695257007715,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-07,1.5820000171661377,1.656000018119812,1.5460000038146973,1.5540000200271606,17633,0.0,0.0,1.5968000054359437,1.6115000039339065,1.5548249969879786,-2.6803597985395915,-0.9121935130051464,3.6451052083494417,45.39613407024296,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-10,1.5420000553131104,1.5420000553131104,1.5180000066757202,1.5299999713897705,6484,0.0,0.0,1.5802000045776368,1.6090000033378602,1.5569749971230824,-3.1768151526669537,-1.7899315537898086,3.3414156496351946,43.83828918132564,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-11,1.5199999809265137,1.5199999809265137,1.4500000476837158,1.4600000381469727,25465,0.0,0.0,1.5688000082969666,1.6048500031232833,1.557808330655098,-6.935235184509168,-2.2463155283146623,3.019734298660672,39.57276926541038,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-12,1.4579999446868896,1.5920000076293945,1.440000057220459,1.5499999523162842,188391,0.0,0.0,1.564800000190735,1.6017500013113022,1.5596916635831197,-0.9458108303071817,-2.3068519488258112,2.696580273536935,46.74723683646999,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-13,1.5499999523162842,1.565999984741211,1.4299999475479126,1.534000039100647,94021,0.0,0.0,1.563200008869171,1.6007500022649765,1.5609916637341181,-1.8679612079613261,-2.3457750018850034,2.5469923673871975,45.70824590867285,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-14,1.5479999780654907,1.5479999780654907,1.4700000286102295,1.5240000486373901,36205,0.0,0.0,1.5592000126838683,1.598300004005432,1.5624249974886577,-2.2575656593209033,-2.4463486969640797,2.2961106340744375,45.034543321344316,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-17,1.5240000486373901,1.6979999542236328,1.5199999809265137,1.6399999856948853,41523,0.0,0.0,1.562600016593933,1.600150004029274,1.564524997274081,4.953280959875081,-2.34665420996705,2.277049380307992,53.58143536088878,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-18,1.6380000114440918,1.6779999732971191,1.5499999523162842,1.6239999532699585,8191,0.0,0.0,1.5652000069618226,1.6019500017166137,1.5664749970038732,3.7567049608101684,-2.2940787612229254,2.264639064178619,52.37177496207227,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-19,1.5219999551773071,1.6360000371932983,1.4500000476837158,1.6360000371932983,55692,0.0,0.0,1.5742000102996827,1.6029500037431716,1.568491663535436,3.9258052654853355,-1.7935676955833073,2.1969093625952283,53.22470567394747,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-20,1.4800000190734863,1.5740000009536743,1.3799999952316284,1.5,166106,0.0,0.0,1.5552000045776366,1.6004500031471252,1.5698249965906144,-3.549382999945909,-2.827329718548466,1.9508548164937463,43.6780361990637,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-21,1.4620000123977661,1.472000002861023,1.350000023841858,1.465999960899353,137072,0.0,0.0,1.546399998664856,1.596400001645088,1.5710416624943415,-5.1991747177262955,-3.1320472894454507,1.61410990912139,41.66595708462675,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-24,1.4119999408721924,1.5219999551773071,1.3940000534057617,1.4700000286102295,34649,0.0,0.0,1.540400004386902,1.5926500022411347,1.5720083296298981,-4.570239910164925,-3.2806955565069527,1.3130765417824688,42.00444972645071,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-25,1.4700000286102295,1.5,1.4079999923706055,1.4700000286102295,52259,0.0,0.0,1.5414000034332276,1.5875000029802322,1.5733083297808965,-4.632150944853108,-2.9039369738872787,0.9020274621766001,42.00444972645071,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-26,1.4199999570846558,1.4600000381469727,1.4199999570846558,1.4259999990463257,84976,0.0,0.0,1.5290000081062316,1.580850002169609,1.5742583294709525,-6.736429595411075,-3.279880696600995,0.41871607570733177,39.10935485708748,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-27,1.399999976158142,1.4259999990463257,1.3700000047683716,1.4240000247955322,36582,0.0,0.0,1.5180000066757202,1.5769000023603439,1.5752083301544189,-6.192357145375728,-3.735176333087746,0.10739355382657202,38.977850088819494,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-02-28,1.4220000505447388,1.4220000505447388,1.3980000019073486,1.3980000019073486,11406,0.0,0.0,1.505400002002716,1.5741000026464462,1.5760416636864345,-7.134316457585182,-4.364398737578852,-0.12319858571800944,37.22544403579739,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-03,1.4900000095367432,1.4900000095367432,1.4019999504089355,1.4199999570846558,1844,0.0,0.0,1.483399999141693,1.5717000007629394,1.57689166367054,-4.273968052697929,-5.6181206068832115,-0.3292339624344181,39.696005665152,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-04,1.4459999799728394,1.4559999704360962,1.2020000219345093,1.4520000219345093,46884,0.0,0.0,1.4662000060081481,1.567950001358986,1.5781916638215383,-0.9684888838801408,-6.489364792413552,-0.6489492181039958,43.197802349231814,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-05,1.4520000219345093,1.5199999809265137,1.2999999523162842,1.3980000019073486,135963,0.0,0.0,1.4424000024795531,1.562150001525879,1.5795083304246267,-3.078203029387051,-7.6657170520984685,-1.0989703925196301,39.07432100811557,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-06,1.3980000019073486,1.5,1.3200000524520874,1.3839999437332153,111688,0.0,0.0,1.4307999968528748,1.5567999988794328,1.5807083298762639,-3.2709011198349778,-8.09352531585633,-1.512507433847876,38.05996281115197,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-07,1.4539999961853027,1.4539999961853027,1.3140000104904175,1.3860000371932983,33567,0.0,0.0,1.4228000044822693,1.551800000667572,1.581924996773402,-2.5864469477817984,-8.312926674172445,-1.9043251840178756,38.30636547137189,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-10,1.350000023841858,1.3899999856948853,1.309999942779541,1.3480000495910645,96395,0.0,0.0,1.4106000065803528,1.5471500009298325,1.5829083303610483,-4.437824804853523,-8.82590532704738,-2.2590271808765854,35.423138596943815,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-11,1.3480000495910645,1.350000023841858,1.3079999685287476,1.350000023841858,11343,0.0,0.0,1.3986000061035155,1.5424000024795532,1.584208330512047,-3.4749021914461915,-9.32313253013911,-2.6390675536329504,35.69746121835584,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-12,1.3639999628067017,1.3639999628067017,1.309999942779541,1.3179999589920044,80053,0.0,0.0,1.3878000020980834,1.5374500006437302,1.5852249970038732,-5.029546260308037,-9.733649776122041,-3.0137675377589512,33.26271593436856,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-13,1.3179999589920044,1.3300000429153442,1.2519999742507935,1.2619999647140503,62286,0.0,0.0,1.3715999960899352,1.5287499994039535,1.5857416629791259,-7.990670143505782,-10.27964044973277,-3.5940068237913603,29.474115602544543,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-14,1.281999945640564,1.4700000286102295,0.7020000219345093,0.7319999933242798,829218,0.0,0.0,1.3049999952316285,1.5053000003099442,1.5821083297332128,-43.90804628360517,-13.30631801216193,-4.854808484335624,13.63976054485957,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-17,0.718999981880188,0.718999981880188,0.6650000214576721,0.6869999766349792,229852,0.0,0.0,1.2316999971866607,1.4796250000596047,1.578083329896132,-44.22343279985684,-16.755934974264203,-6.239108415333669,13.001112446979903,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-18,0.6869999766349792,0.699999988079071,0.6800000071525574,0.6949999928474426,80134,0.0,0.0,1.1559999942779542,1.453499999642372,1.573041663567225,-39.87889305470589,-20.467836631414972,-7.599395915157481,13.774069990355528,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-19,0.6880000233650208,0.7400000095367432,0.6629999876022339,0.7400000095367432,107172,0.0,0.0,1.0901999950408936,1.4296999990940094,1.568474997083346,-32.122545138244504,-23.746240768570644,-8.847766030532549,18.177789408839146,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-20,0.7829999923706055,0.7829999923706055,0.7099999785423279,0.734000027179718,106064,0.0,0.0,1.0252000033855437,1.4056000009179115,1.5642249976595244,-28.4042113972092,-27.06317567472622,-10.14080435864124,18.045455365983955,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-21,0.746999979019165,0.746999979019165,0.6579999923706055,0.6890000104904175,140271,0.0,0.0,0.9555000007152558,1.380375002324581,1.55886666427056,-27.891155418665114,-30.779679499688616,-11.450091661912627,17.043307562377535,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-24,0.6800000071525574,0.7229999899864197,0.6439999938011169,0.7089999914169312,95991,0.0,0.0,0.8915999948978424,1.3557000026106834,1.5540416643023491,-20.480036398142097,-34.23323794490813,-12.762956505461947,19.19125613585601,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-25,0.6972439885139465,0.6972439885139465,0.63332200050354,0.6972439885139465,82839,0.0,0.0,0.8263243913650513,1.3337811022996902,1.5487853646278382,-15.621032635605694,-38.04647629657429,-13.882121256989796,18.881777892947184,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-26,0.6972439885139465,0.6972439885139465,0.6490560173988342,0.6569240093231201,23215,0.0,0.0,0.7602167963981629,1.3104542016983032,1.5430930644273757,-13.58728030799036,-41.98829723213919,-15.07613948193087,17.820355185121898,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-27,0.6893770098686218,0.7011780142784119,0.6451230049133301,0.6893770098686218,70825,0.0,0.0,0.70295450091362,1.2889386281371116,1.5372712060809135,-1.9314893108091202,-45.462531297584576,-16.15411626533328,21.63862638108074,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-28,0.6834759712219238,0.6903600096702576,0.6392220258712769,0.6903600096702576,45537,0.0,0.0,0.6987905025482177,1.2670976281166078,1.5313575396935144,-1.2064406781742776,-44.85109220929661,-17.256578214242218,21.757211471199028,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-03-31,0.7267460227012634,0.7277299761772156,0.6667580008506775,0.6785590052604675,122145,0.0,0.0,0.6979464054107666,1.2439116045832634,1.525428864856561,-2.777777777777775,-43.890996527474854,-18.454958258559582,21.33970172465223,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-01,0.6982269883155823,0.7031440138816833,0.6785590052604675,0.693310022354126,55026,0.0,0.0,0.697777408361435,1.22129435390234,1.5196397816141447,-0.6402308177044027,-42.86574680936973,-19.63264132207078,23.32045591964426,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-02,0.6982269883155823,0.6982269883155823,0.6411889791488647,0.6765919923782349,28904,0.0,0.0,0.6914366066455842,1.1995591536164283,1.513778048257033,-2.1469233946646282,-42.359107130228416,-20.75726325945848,22.625090425893433,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-03,0.6880000233650208,0.6880000233650208,0.6869999766349792,0.6869999766349792,7382,0.0,0.0,0.6867366015911103,1.1744841516017914,1.507986381649971,0.038351682909976925,-41.528661697603894,-22.115732217904807,24.141602846225283,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-04,0.699999988079071,0.7160000205039978,0.6309999823570251,0.6919999718666077,68209,0.0,0.0,0.6870365977287293,1.1529341503977775,1.5018363818526268,0.7224322771576928,-40.409727867659,-23.231707239935982,24.903077763285836,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-07,0.6919999718666077,0.6940000057220459,0.6000000238418579,0.6899999976158142,86672,0.0,0.0,0.6851365983486175,1.1319341510534286,1.4956697156031926,0.7098437419514495,-39.47204457865339,-24.3192437979579,24.795859048614986,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-08,0.6880000233650208,0.6880000233650208,0.621999979019165,0.6499999761581421,17433,0.0,0.0,0.6804121971130371,1.111684149503708,1.4893863817056021,-4.469676041072298,-38.79446806749963,-25.359586796366468,22.691582302288367,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-09,0.6600000262260437,0.6600000262260437,0.6399999856948853,0.6499999761581421,57304,0.0,0.0,0.6797197937965394,1.0891841500997543,1.483136381705602,-4.372363128105889,-37.59367562094194,-26.56210423162865,22.691582302288367,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-10,0.6299999952316284,0.6620000004768372,0.6299999952316284,0.6439999938011169,16692,0.0,0.0,0.6751820921897889,1.0669341489672661,1.4760030483206112,-4.618324263835311,-36.7175478596005,-27.714637840266093,22.361453930047404,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-11,0.6520000100135803,0.6600000262260437,0.6420000195503235,0.6420000195503235,81448,0.0,0.0,0.6703460931777954,1.0448841482400895,1.4681363821029663,-4.228572958946696,-35.84493608149123,-28.82921770909376,22.245278302367083,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-14,0.6399999856948853,0.6539999842643738,0.6399999856948853,0.6520000100135803,52561,0.0,0.0,0.6676901936531067,1.0201841488480567,1.4587363824248314,-2.349919736529493,-34.55199295077947,-30.063844218910692,24.361294284815344,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-15,0.6480000019073486,0.656000018119812,0.6320000290870667,0.656000018119812,174602,0.0,0.0,0.6639591932296753,0.9959841504693031,1.4495363826553027,-1.1987446203053183,-33.33636956804776,-31.28946866136395,25.237731104570727,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-16,0.6539999842643738,0.6639999747276306,0.6480000019073486,0.6639999747276306,103566,0.0,0.0,0.6626999914646149,0.9716841489076614,1.4401530494292578,0.19616467176084731,-31.798826582732403,-32.52910520220429,27.058123041578796,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-17,0.6600000262260437,0.7099999785423279,0.6359999775886536,0.7099999785423279,188155,0.0,0.0,0.6649999916553497,0.9519341483712196,1.4299863830208779,6.766915406263696,-30.14222750668421,-33.43054453705792,36.615150111849175,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-22,0.7099999785423279,0.7099999785423279,0.6460000276565552,0.6660000085830688,124888,0.0,0.0,0.6623999953269959,0.9319341495633126,1.4180780495206515,0.5434802659223745,-28.922017114901895,-34.281885973883355,32.26100437304132,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-23,0.6840000152587891,0.722000002861023,0.6600000262260437,0.7139999866485596,348915,0.0,0.0,0.6647999942302704,0.9130341485142708,1.4067363823453585,7.400720945440854,-27.187828044322103,-35.09557583262122,40.5645074478236,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-24,0.7200000286102295,0.7200000286102295,0.6600000262260437,0.6600000262260437,905412,0.0,0.0,0.6657999992370606,0.8927841484546661,1.3953613817691803,-0.8711284195949308,-25.42430324401435,-36.01771124533315,35.31920428203637,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-25,0.6620000004768372,0.6779999732971191,0.6600000262260437,0.6600000262260437,208218,0.0,0.0,0.6668000042438507,0.873634149134159,1.3833613827824593,-1.019792737631746,-23.675144234608673,-36.84700469396127,35.31920428203637,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-28,0.6679999828338623,0.6700000166893005,0.656000018119812,0.656000018119812,257134,0.0,0.0,0.6680000066757202,0.8544341489672661,1.3743780498703322,-1.7964054544888057,-21.819603361696664,-37.83121397726928,34.93116627077603,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-29,0.6639999747276306,0.7720000147819519,0.6019999980926514,0.6019999980926514,285989,0.0,0.0,0.664000004529953,0.8345341488718987,1.3639113828539848,-9.337350303362056,-20.43465142468637,-38.81316928922202,30.12013665641635,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-04-30,0.6399999856948853,0.6399999856948853,0.6039999723434448,0.6039999723434448,196983,0.0,0.0,0.6592000007629395,0.8141341492533684,1.3530113831162454,-8.373790709285151,-19.030542894253596,-39.82798966714819,30.50191645088364,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-02,0.6200000047683716,0.6539999842643738,0.6000000238418579,0.6200000047683716,117959,0.0,0.0,0.6555999994277955,0.7933341488242149,1.3420947169264157,-5.430139519599661,-17.361429556581243,-40.88836362897986,33.62611944415529,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-05,0.6499999761581421,0.6639999747276306,0.6039999723434448,0.628000020980835,85450,0.0,0.0,0.6520000040531159,0.7740841493010521,1.3313613836963971,-3.680978975933522,-15.771430710494498,-41.857698534722275,35.194787462422326,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-06,0.6000000238418579,0.6759999990463257,0.5600000023841858,0.5600000023841858,375318,0.0,0.0,0.6370000064373016,0.7534841507673263,1.3192780504624049,-12.087912602037742,-15.459402060600835,-42.88663026696826,28.934993134457883,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-07,0.6399999856948853,0.6399999856948853,0.5320000052452087,0.5680000185966492,142332,0.0,0.0,0.6272000074386597,0.7330341503024101,1.3081780508160592,-9.438773619243026,-14.437818868341818,-43.96526146841146,30.50111683527747,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-08,0.5799999833106995,0.5899999737739563,0.550000011920929,0.5519999861717224,166118,0.0,0.0,0.6110000073909759,0.7131341487169266,1.2970780511697133,-9.656304501728048,-14.321869385964867,-45.01995095254155,29.118949448829994,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-09,0.6019999980926514,0.6019999980926514,0.550000011920929,0.5799999833106995,128305,0.0,0.0,0.6030000030994416,0.6938841477036476,1.2867780511577924,-3.814265285326896,-13.097884553924398,-46.07584835012395,34.69602258991689,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-12,0.3709999918937683,0.48399999737739563,0.36000001430511475,0.46000000834465027,1037123,0.0,0.0,0.5830000013113021,0.6724341489374638,1.2762947174410024,-21.09776890051396,-13.300060350516047,-47.31356795978061,25.452859336505767,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-13,0.41100001335144043,0.4880000054836273,0.4099999964237213,0.4390000104904175,217896,0.0,0.0,0.5613000005483627,0.6518591500818729,1.2664697172741095,-21.788702999904526,-13.892441261603222,-48.52943254854098,24.236041952512196,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-14,0.4449999928474426,0.45100000500679016,0.4059999883174896,0.45100000500679016,398916,0.0,0.0,0.5462000012397766,0.6448341503739357,1.2553947175542512,-17.42951226966303,-15.29604923637522,-48.63494792855304,26.401279613679023,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-15,0.48100000619888306,0.48100000619888306,0.4169999957084656,0.46299999952316284,103514,0.0,0.0,0.5321000039577484,0.6392341509461403,1.2457863837480545,-12.986281511110917,-16.75976585885173,-48.68830167954237,28.59880097655727,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-16,0.41999998688697815,0.4779999852180481,0.4180000126361847,0.4390000104904175,129084,0.0,0.0,0.514000004529953,0.6328341513872147,1.2371447175741195,-14.591438400496148,-18.778086896348643,-48.84720094605258,26.870747159772435,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-19,0.4790000021457672,0.4790000021457672,0.4009999930858612,0.4699999988079071,495939,0.0,0.0,0.4982000023126602,0.6260841511189937,1.2286613839368026,-5.660378035698072,-20.426031960363076,-49.04339313465418,32.54078420908576,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-20,0.4580000042915344,0.46000000834465027,0.41999998688697815,0.42399999499320984,102953,0.0,0.0,0.48460000157356264,0.618334150314331,1.2196113839745522,-12.50516021122086,-21.628135640378986,-49.30072329275397,28.953418671909276,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-21,0.42399999499320984,0.42899999022483826,0.41200000047683716,0.41200000047683716,206304,0.0,0.0,0.4689999997615814,0.6114091500639915,1.2103613843520482,-12.153517977339124,-23.29195601464343,-49.485405105575,28.083639760528385,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-22,0.4020000100135803,0.42899999022483826,0.39100000262260437,0.4129999876022339,418223,0.0,0.0,0.45509999990463257,0.6040091499686241,1.2007697174946468,-9.250716833931191,-24.65345931791377,-49.69816933517755,28.276999262501633,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-23,0.40799999237060547,0.4749999940395355,0.4050000011920929,0.4690000116825104,951470,0.0,0.0,0.44400000274181367,0.5983030505478382,1.1915280513465405,5.630632609530462,-25.79011550496632,-49.786910188837055,38.284201181701675,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-26,0.4300000071525574,0.46700000762939453,0.4300000071525574,0.44699999690055847,395980,0.0,0.0,0.44270000159740447,0.5930549502372742,1.180736384789149,0.9713113367152094,-25.352616748197534,-49.77245066067991,36.15024777761176,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-27,0.4490000009536743,0.44999998807907104,0.4259999990463257,0.44699999690055847,296951,0.0,0.0,0.44350000023841857,0.5869955249130726,1.169878051429987,0.7891762480853125,-24.445761268095545,-49.82421251552113,36.15024777761176,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-28,0.44999998807907104,0.47600001096725464,0.4230000078678131,0.4410000145435333,190510,0.0,0.0,0.4425000011920929,0.5807615250349045,1.1582197179396947,-0.33898003265956866,-23.80693587346406,-49.85739613654694,35.52394703914119,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-05-30,0.4690000116825104,0.4690000116825104,0.4350000023841858,0.43700000643730164,121240,0.0,0.0,0.43990000188350675,0.5747225500643254,1.146711385001739,-0.6592396985197301,-23.458719022896997,-49.88080195406329,35.08751181092599,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-02,0.4560000002384186,0.4560000002384186,0.4009999930858612,0.4090000092983246,645768,0.0,0.0,0.4369000017642975,0.5676147997379303,1.1358697180946669,-6.385898913551536,-23.028786077104446,-50.028177466509106,32.11334120310963,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-03,0.4090000092983246,0.41499999165534973,0.4090000092983246,0.41499999165534973,23982,0.0,0.0,0.43140000104904175,0.5610749997198582,1.1248280512789885,-3.801578431574379,-23.11188321268324,-50.1190427210731,33.41579167003859,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-04,0.4350000023841858,0.4350000023841858,0.4189999997615814,0.41999998688697815,168042,0.0,0.0,0.43100000023841856,0.5543999999761582,1.1143447180589041,-2.5522072727042855,-22.258297211949206,-50.248788279637836,34.542829030828,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-05,0.43700000643730164,0.43700000643730164,0.4090000092983246,0.4180000126361847,147344,0.0,0.0,0.43160000145435334,0.5475500009953975,1.1039947184423606,-3.1510632002643786,-21.176148174642922,-50.40284234620774,34.292789095165375,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-09,0.4090000092983246,0.43799999356269836,0.4020000100135803,0.4169999957084656,142835,0.0,0.0,0.4320000022649765,0.5407250009477138,1.093886385113001,-3.472223721728206,-20.107263117514083,-50.568449492873455,34.15964177992356,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-10,0.41499999165534973,0.44999998807907104,0.41499999165534973,0.44999998807907104,146116,0.0,0.0,0.43009999990463255,0.5357250012457371,1.0840863846242428,4.626828221076723,-19.71627254570752,-50.58281250977746,42.14285576059129,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-11,0.46299999952316284,0.46299999952316284,0.4410000145435333,0.4410000145435333,21097,0.0,0.0,0.42950000166893004,0.5305000022053719,1.0738113845388095,2.677535001144842,-19.038642811794336,-50.59653773057957,40.69366851073379,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-12,0.4359999895095825,0.48100000619888306,0.4359999895095825,0.44600000977516174,458319,0.0,0.0,0.42940000295639036,0.525550002604723,1.0644113846123218,3.8658608999723905,-18.295119241136984,-50.62529298330101,41.889225405238705,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-13,0.460999995470047,0.460999995470047,0.42500001192092896,0.4350000023841858,28309,0.0,0.0,0.4288000017404556,0.5203750021755695,1.0545197181403636,1.445895666642955,-17.597886149845717,-50.65289029462187,39.97973630765963,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-16,0.4970000088214874,0.4970000088214874,0.44600000977516174,0.44600000977516174,83445,0.0,0.0,0.42970000207424164,0.5152250021696091,1.0451863850156466,3.793345967474271,-16.599543837201658,-50.70496424789383,42.788300691766324,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-17,0.46799999475479126,0.46799999475479126,0.43700000643730164,0.46799999475479126,125155,0.0,0.0,0.4356000006198883,0.5105250015854835,1.0361530512571335,7.438015171899812,-14.676068896314302,-50.72880391887291,48.02650570842937,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-18,0.460999995470047,0.46799999475479126,0.4399999976158142,0.46799999475479126,13374,0.0,0.0,0.44090000092983245,0.5056250020861626,1.0267530515789987,6.146517071400885,-12.800989051032024,-50.75495501975047,48.026505708429376,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-19,0.4429999887943268,0.515999972820282,0.41999998688697815,0.5120000243186951,355387,0.0,0.0,0.45010000467300415,0.5006750032305718,1.0176863849163056,13.752503666526517,-10.101362806458454,-50.8026234160785,57.1307427121656,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-23,0.5120000243186951,0.5120000243186951,0.44999998807907104,0.44999998807907104,83775,0.0,0.0,0.4533000022172928,0.4952750027179718,1.0078697179754574,-0.7279978208868049,-8.475089651270201,-50.859223778163745,45.13343746915462,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
2025-06-24,0.47699999809265137,0.49300000071525574,0.4410000145435333,0.4740000069141388,64862,0.0,0.0,0.4590000033378601,0.48927500322461126,0.9983197179933389,3.2679746115900334,-6.187726674614687,-50.99014930727073,49.549952759815014,,-0.211,-0.33418,0.57867,-1.47155,,9.115384,0.3646154,Sprint Bioscience AB (publ),Healthcare,"Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden."
